Control of DNA replication by NCOA4 protein in HeLa cells by Provitera, Livia
Doctorate Program in Molecular Oncology 
and Endocrinology 
Doctorate School in Molecular Medicine 
 
 
 
XXI cycle - 2005–2008 
Coordinator: Prof. Giancarlo Vecchio 
 
 
 
 
 
 
“Control of DNA replication by NCOA4 
protein in HeLa cells” 
 
 
Livia Provitera 
 
 
 
 
 
University of Naples Federico II 
Dipartimento di Biologia e Patologia Cellulare e Molecolare 
“L. Califano” 
 
 
 
Administrative Location 
 
Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Califano” 
Università degli Studi di Napoli Federico II 
 
Partner Institutions 
 
Italian Institutions 
Università di Napoli “Federico II”, Naples, Italy 
Istituto di Endocrinologia ed Oncologia Sperimentale “G. Salvatore”, CNR, Naples, Italy 
Seconda Università di Napoli, Naples, Italy 
Università del Sannio, Benevento, Italy 
Università di Genova, Genoa, Italy 
Università di Padova, Padua, Italy 
 
Foreign Institutions 
Johns Hopkins School of Medicine, Baltimore, MD, USA 
Johns Hopkins Krieger School of Arts and Sciences, Baltimore, MD, USA 
National Institutes of Health, Bethesda, MD, USA 
Ohio State University, Columbus, OH, USA 
Université Paris Sud XI, Paris, France 
Universidad Autonoma de Madrid, Spain  
Centro de Investigaciones Oncologicas (CNIO), Spain  
Universidade Federal de Sao Paulo, Brazil  
Albert Einstein College of Medicine of Yeshiwa University, USA 
 
 
Supporting Institutions 
Università di Napoli “Federico II”, Naples, Italy 
Ministero dell’Istruzione, dell’Università e della Ricerca 
Istituto Superiore di Oncologia (ISO) 
Terry Fox Foundation, Canada 
Istituto di Endocrinologia ed Oncologia Sperimentale “G. Salvatore”, CNR, Naples, Italy 
Centro Regionale di Competenza in Genomica (GEAR) 
 
 
 
FACULTY 
 
ITALIAN FACULTY 
Giancarlo Vecchio, MD, Co-ordinator 
Salvatore Maria Aloj, MD 
Francesco Beguinot, MD 
Maria Teresa Berlingieri, PhD 
Angelo Raffaele Bianco, MD 
Bernadette Biondi, MD 
Francesca Carlomagno, MD 
Gabriella Castoria, MD 
Angela Celetti, MD 
Annamaria Cirafici, PhD 
Mario Chiariello, MD 
Vincenzo Ciminale, MD  
Annamaria Colao, MD 
Alma Contegiacomo, MD 
Sabino De Placido, MD 
Monica Fedele, PhD  
Pietro Formisano, MD 
Alfredo Fusco, MD 
Fabrizio Gentile, MD, PhD  
Massimo Imbriaco, MD 
Paolo Laccetti, PhD 
Antonio Leonardi, MD 
Barbara Majello, PhD 
Rosa Marina Melillo, MD 
Claudia Miele, PhD 
Roberto Pacelli, MD 
Giuseppe Palumbo, PhD 
Angelo Paradiso MD, PhD 
Silvio Parodi, MD 
Giuseppe Portella, MD 
Giorgio Punzo, MD 
Antonio Rosato, MD 
Massimo Santoro, MD 
Giampaolo Tortora, MD 
Donatella Tramontano, PhD 
Giancarlo Troncone, MD 
Bianca Maria Veneziani, MD 
Giuseppe Viglietto, MD 
Roberta Visconti, MD
FOREIGN FACULTY 
Université Libre de Bruxelles (Belgium) 
Gilbert Vassart 
Universidade Federal de Sao Paulo (Brazil) 
Janete Maria Cerutti  
Rui Maciel 
University of Turku (Finland) 
Mikko O. Laukkanen 
Université Paris Sud XI (France) 
Martin Schlumberger, MD 
University of Madras (India) 
A.K: Munirajan 
Pavol Jozef Šafàrik University (Slovakia) 
Peter Fedorocko 
Universidad Autonoma de Madrid (Spain) 
Juan Bernal, MD, PhD 
Pilar Santisteban 
Centro de Investigaciones Oncologicas (Spain) 
Mariano Barbacid, MD 
Albert Einstein College of Medicine of Yeshiwa 
University (USA) 
Luciano D’Adamio, MD 
Nancy Carrasco 
Johns Hopkins School of Medicine (USA) 
Vincenzo Casolaro, MD 
Pierre Coulombe, PhD 
James G. Herman MD 
Robert Schleimer, PhD 
Johns Hopkins Krieger School of Arts and 
Sciences (USA) 
Eaton E. Lattman, MD 
National Institutes of Health (USA) 
Michael M. Gottesman, MD 
Silvio Gutkind, PhD 
Stephen Marx, MD 
Ira Pastan, MD 
Phil Gorden, MD 
Ohio State University, Columbus (USA) 
Carlo M. Croce, MD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Control of DNA 
replication by NCOA4 
protein in HeLa cells” 
 5
 
TABLE OF CONTENTS 
 
LIST OF PUBLICATIONS………………………………………………......8 
ABSTRACT…………………………………………………………………...9 
1. BACKGROUND..........................................................................................10
 1.1 Thyroid cancer………………………….………………...……….10 
1.2 RET/PTC3 oncogene…………………………………….……......11 
1.3 NCOA4 (RFG/ELE1alpha/ARA70)……………………………....15 
1.4Minichromosome maintenance (MCM) proteins and DNA 
replication……………………………………………………………..17 
1.5 MCM proteins and cancer………………………………………...19 
1.6 Analysis of NCOA4-MCM7 interaction and its functional role in 
Xenopus laevis egg extract …………………………………………...19 
2. AIMS OF THE STUDY…………………………………………………..22 
3. MATERIAL AND METHODS…………………………………………..23 
 3.1 Recombinant proteins…………………………………………….23
 3.2 Protein studies……………………………………………………..23 
 3.3 Cell fractionation and analysis of nuclear fractions………………23 
 3.4 Cell culture methods, immunofluorescence and cytofluorimetric 
 analysis………………………………………………………………..24 
 3.5 Chromatin immunoprecipitation (ChIP)…………………………..26 
4. RESULTS AND DISCUSSIONS………………………………………...27 
 4.1 NCOA4 and MCM7 interact in the nucleus in HeLa cells………..27 
4.2 NCOA4 protein binds to DNA replication origins in HeLa cells....29 
4.3 NCOA4 protein levels change during the cell cycle phases in HeLa 
cells……………………………………………………………………30 
4.4 NCOA4 protein affects cell growth and DNA synthesis rate in HeLa 
cells…………………………………………………..………………..31 
5. CONCLUSIONS………………………………………………………......38 
6. AKNOWLEDGEMENTS…………………………………..…………….39 
 6
7. REFERENCES………………………………………………..…………..40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7
LIST OF PUBLICATIONS 
 
 
 
1) Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, 
Provitera L, Basolo F, Fusco A, Carlomagno F and Santoro M. Mitogenic 
effects of the up-regulation of minichromosome maintenance proteins in 
anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2005 Aug; 90(8):4703-
9. 
 
2)  Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, 
Santoro M and Carlomagno F. Sorafenib inhibits imatinib-resistant KIT and 
platelet-derived growth factor receptor beta gatekeeper mutants. Clin Canc Res 
2007 Jun 1; 13(11): 3363-9.  
3)  Carlomagno F, Guida T, Anaganti S, Provitera L, Kjaer S, Mc Donald 
NQ, Ryan AJ and Santoro M. Identification of tyrosine 806 as a molecular 
determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer 2008 
Nov 24. 
4)  Carlomagno F, Guida T, Provitera L, Vitagliano D, Dathan N, Grieco 
D, Costanzo V, Fusco A and Santoro M. Protein NCOA4 inhibits initiation 
of eukaryotic DNA replication. (2008 submitted) 
 
5) Guida T, Provitera L et al. RET oncogenic mutants are HSP90 client 
proteins whose stability is affected by 17-AAG treatment. (in preparation) 
 
6)  Provitera L, Guida T, Santoro M and Carlomagno F. Effect of NCOA4 
ubiquitination on cell cycle and DNA replication. (in preparation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8
ABSTRACT 
 
 
 
This dissertation is focused on the functional characterization of 
NCOA4 protein, and in particular on its role in controlling DNA replication in 
HeLa cells. 
In human papillary thyroid carcinoma the rearrangement of RET 
protooncogene, in particular of its tyrosine kinase domain, with the 5’ portion 
of a number of heterologous genes, generates the RET/papillary thyroid 
carcinoma (PTC) oncogenes. One of the most frequent and aggressive variants 
of these recombination events is the fusion of the intracellular kinase-encoding 
domain of RET to the first 238 amino acids of a gene named NCOA4 
(ELE1/ARA70/RFG), generating the RET/PTC3 oncogene. 
We previously isolated the Mini-Chromosome Maintenance 7 (MCM7) protein 
as an interactor of NCOA4.  
MCM7 is a component of an heteroexameric complex named MCM2-7, 
considered a master regulator of DNA replication, acting both during DNA 
replication origins licensing, as part of the Pre-Replication Complex (Pre-RC), 
and during nascent strand elongation, as the major helicase of the fork. In 
Xenopus laevis egg extracts NCOA4 blocks DNA replication. Hindrance of 
DNA replication is mediated by block of MCM2-7 helicase function, leaving 
untouched origin licensing and activation. 
Here we show that NCOA4 and MCM7 proteins interact at the 
endogenous level in HeLa cells and this interaction is confined in the nucleus 
and takes place preferentially on chromatin. 
Moreover, in HeLa cells, NCOA4 binds canonical DNA replication origins, 
such as those prospicient to the c-Myc or to the Lamin B2 gene.  
RNAi-mediated depletion of NCOA4 accelerates the onset of DNA replication, 
whereas adoptive NCOA4 overexpression decreases cell growth and DNA 
synthesis. 
Our results suggest that NCOA4/RET rearrangement might represent a 
novel paradigm of a cancer-associated chromosome rearrangement that directly 
targets a gene that controls cell proliferation. 
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1.   BACKGROUND 
 
 
 
1.1 THYROID CANCER 
 
 
Thyroid carcinoma are divided into well-differentiated, poorly 
differentiated and undifferentiated types on the basis of the histological and 
clinical parameters (Fig.1). Differentiated tumors (papillary and follicular) are 
highly treatable and usually curable. Poorly differentiated tumors (medullary 
and anaplastic) are much less common, more aggressive and metastatize early 
displaying a poorer prognosis.  
 
 
 
Figure 1 - Classification of thyroid carcinomas. 
 
 
Papillary thyroid carcinoma (PTCs) account for around 60 to 80% of all 
thyroid cancers and are closely linked to exposure to ionizing irradiation (Ron 
et al. 1995). Young children are particularly susceptible since thyroid growth 
occurs primarly in childhood. A striking increase in pediatric PTC has been 
reported in Belarus, Ukraine, and Western regions of the Russia, following the 
Chernobyl disaster of 1986. The worldwide incidence of thyroid cancer in 
children has been estimated in the order of 1 per million children per year, 
while it increased by more than 30 fold after the Chernobyl disaster in the 
exposed areas (Williams 2002). PTC shows typically multicentricity and a 
tendency to spread into lymphatic vessels; regional node metastases at 
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presentation are found in a significant proportion of cases. There are several 
PTC variants including solid-follicular, follicular, tall-cell, hurthle cell variants 
(Ostrowski et al. 1996). 
About 10 to 30% of thyroid cancers are follicular thyroid carcinomas 
(FTCs). FTC is linked to dietary iodine deficiency (Williams et al. 1997) and 
shows variable morphology ranging from well-formed colloid-containing 
follicles, to solid or trabecular growth pattern.  
Anaplastic thyroid carcinoma (ATC) is the most aggressive type of 
thyroid cancer. ATC cells are extremely abnormal and spread rapidly to other 
parts of the body.  
Medullary thyroid carcinoma (MTC) derived from neuroendocrine C 
cells of the thyroid, producing calcitonin (CT). About 5 to 7% of all thyroid 
cancers are MTC. MTC can be sporadic or familial as part of the Multiple 
Endocrine Neoplasia type 2 syndromes.  
 
 
1.2 RET/PTC3 ONCOGENE 
 
 
Papillary thyroid carcinoma (PTCs) are characterized by activating, 
non-overlapping events that involve the genes RET, NTRK1 (neurotrophic 
tyrosine kinase receptor 1), BRAF or Ras. 
The REarranged during Transfection (RET) proto-oncogene was 
isolated in 1985 and was the first activated receptor-tyrosine kinase to be 
identified in thyroid cancer (Fusco et al. 1987; Takahashi et al. 1988). The 
proto-oncogene, located on chromosome 10q11.2, is composed by 21 exons 
and has a size of about 55 kb. It encodes a transmembrane receptor-tyrosine 
kinase with four cadherin-related motifs and a cysteine-rich region in the 
extracellular domain and an intracellular portion containing the juxtamembrane 
region, the tyrosine kinase domain (TK) split in two subdomains by the 
insertion of 27 amino acids and a COOH tail where several tyrosines function 
as autophosphorylation sites. 
RET is normally expressed in the developing central and peripheral nervous 
systems and is an essential component of a signalling pathway that is required 
for renal organogenesis, enteric neurogenesis and spermatogenesis (Schuchardt 
et al. 1994). Glial-derived neurotrophic  factor (GDNF)-family ligands and 
GDNF-family receptor alpha (GFRalpha) bind the extracellular domain of RET 
to induce tyrosine kinase autophosphorylation that activates several signalling 
pathways, including extracellular regulated kinase (ERK), phosphatidylinositol 
3-kinase (PI3K), MAPK p38 and c-JUN kinase (JNK). 
Gain-of-function mutations of RET are involved in sporadic and familial C-
cell-derived medullary thyroid carcinoma, including multiple endocrine 
neoplasia 2A (MEN2A), MEN2B and familial medullary thyroid carcinoma 
(FMTC) (Brandi et al. 2001). 
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By contrast, chimeric oncogenes, designated RET/PTC, are implicated in the 
development of papillary carcinoma. Somatic chromosomal rearrangement 
leads to fusion of the 3’-terminal sequence of RET, which encodes the tyrosine 
kinase domain, with the 5’-terminal sequences of heterologus genes (Fig. 2). 
 
 
 
 
Figure 2 - RET rearrangements. Schematic drawing of the RET protein with the four 
extracellular cadherin-like domains, the cysteine-rich box adjacent to the plasma membrane, 
the juxtamembrane domain and the split tyrosine kinase domain (TK). In PTCs, RET is 
rearranged with diverse genes, encoding protein dimerization motifs (highlighted) that mediate 
ligand-independent RET dimerization. The arrowheads indicate RET and partner genes 
breakpoints. 
 
 
Rearrangements involving the RET gene are common in radiation-
associated papillary thyroid cancer (PTC) and patients with a history of 
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medical irradiation. Although wild-type RET is not expressed in normal 
follicular cells, RET/PTC chimeric oncoproteins, that lack a signal peptide and 
transmembrane domain, are expressed in the cytoplasm of follicular cells under 
the control of the newly acquired promoters. Ligand-indipendent tyrosine 
phosphorylation is induced by the constitutive activation of the fusion proteins 
mediated by the dimerization motifs, i.e. coiled-coil domains, of the partner 
sequences. 
More than 10 RET/PTC rearrangements have been described in sporadic and 
radiation-associated papillary thyroid carcinoma. Among them the most 
common forms are H4(D10S170)/RET (also known as RET/PTC1) (Grieco et 
al. 1990) and NCOA4/RET (also known as RET/PTC3) (Santoro et al. 1994; 
Bongarzone et al. 1994). 
In this dissertation we will focus on RET/PTC3 rearrangement which is 
frequent in radiation induced tumors and in the more aggressive PTC variants, 
like the solid follicular one. 
The RET/PTC3 rearrangement results from a paracentric inversion of 
the long arm of chromosome 10 and is formed by fusion of the intracellular 
domain of RET tyrosine kinase receptor gene with the NCOA4 
(ELE1/RFG/ARA70) gene (Santoro et al. 1994). Both genes are located at 
10q11.2, with a minimum distance of 500 kb between them (Minoletti et al. 
1994). The NCOA4 gene is expressed ubiquitously and drives the expression 
of the truncated RET receptor in thyroid follicular cells (Nikiforov et al. 1999) 
(Fig. 3). 
 
 
Figure 3 - Putative mechanism of RET/PTC3 rearrangement. Schematic steps of RET/PTC3 
formation starting from the linear arrangement of the wild-type genes in the long arm of 
chromosome 10 (top), to formation of chromosomal loop juxtaposing the two genes adjacent to 
each other but pointed in opposite directions, to simultaneous breaks in both genes at the same 
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sites with reciprocal exchange via end-joining leading to inversion and gene rearrangement as 
demonstrated in a linear fashion (bottom). Note that as a result of this reciprocal 
recombination the regions 1 and 2, internal to the target genes, are also inverted. 
 
 
In RET/PTC3 rearrangement, the unscheduled expression of RET 
tyrosine kinase (mechanism n. 1), the deletion of negative regulatory domains 
of the receptor (mechanism n. 2) and constitutive oligomerization of PTC3 
proteins (mechanism n. 3) are responsible for PTC3-transforming activity in 
the thyroid (Santoro et al. 2006) (Fig. 4).  
Thus, the rearrangement deletes the signal sequence, the extracellular 
ligand-binding domain and the intracellular juxtamembrane domains of the 
receptor, which negatively affect RET mitogenic signalling (Melillo et al. 
2004). In addition, the amino terminal region of NCOA4 is responsible for the 
dimerization of the PTC3 oncoprotein in vivo. This region contains a putative 
coiled-coil domain, which mediates protein-protein interaction and is essential 
for tyrosine auto-phosphorylation and the transforming activation of PTC3 
(Monaco et al. 2001).  
 Whereas wild-type RET is a transmembrane protein, as a further 
consequence of the rearrangement (mechanism n. 4), RET/PTC oncoproteins 
are re-localized to the cytosolic compartment. This could prevent RET/PTC 
from interacting with negative regulators located at the plasma membrane 
level, for instance, the tyrosine phosphatase protein tyrosine phosphatase 
receptor type-J (PTPRJ) (Iervolino et al. 2006) (Fig. 4). Finally, RET/PTC 
rearrangements, besides activating RET, can also alter the function of RET-
fused genes, further contributing to neoplastic transformation (mechanism n. 5) 
(Fig. 4). Perhaps, the best example of a RET fusion partner, whose altered 
function may be involved in cancer development, is the regulatory subunit type 
1-α of protein kinase A (PRKAR1A) that is fused to RET in RET/PTC2. 
PRKAR1A is, indeed, a bona fide tumor suppressor, whose germline genetic 
inactivation is associated to the cancer susceptibility syndrome called Carney 
Complex, characterized by high penetrant predisposition to thyroid cancer 
(Bossis and Stratakis 2004). Moreover, RIα ablation in the mouse induced the 
formation of thyroid tumors (Griffin et al. 2004). Also H4(D10S170) gene, 
RET partner in RET/PTC1, displays “tumour suppressor”-like features, acting 
as a proapoptotic protein involved in DNA damage response (Merolla et al. 
2007) (Fig.4). 
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Figure 4 - Mechanisms for RET/PTC activation. The rearrangement RET/PTC may act at 
various levels. It determines the unscheduled expression of RET tyrosine kinase, the deletion of 
negative regulatory domains, the constitutive oligomerization of PTC proteins, mediated by the 
coiled coil domain. Together with the relocalization and the altered function of the RET fusion 
partner, these mechanism are suspected to be responsible for the RET/PTC3 transforming 
activity in the thyroid. The wild type RET protein, the PTPRJ tyrosine phosphatase and the 
rearranged RET/PTC3 oncoprotein are shown. 
 
 
1.3   NCOA4 (RFG/ELE1alpha/ARA70) 
 
   
In the various RET/PTC oncoproteins, little is known about the normal 
role of the 5’ fusion partners. As said, some common features such as 
constitutive expression and the presence of dimerization domains have been 
observed for all the RET-fused genes identified so far.  
Although several data indicate that activation of the RET kinase is critical to 
the transforming properties, it is obscure whether disruption of the normal 
function of the 5’ partner gene might also have an important role. To address 
this point, the identification of the normal physiological function of the 
heterologous RET fusion partners is required to shed light on their role in 
cellular homeostasis. Therefore, we have studied the product of one of the most 
frequently observed RET-fused gene, NCOA4 (RFG/ELE1/ARA70). 
The NCOA4 gene maps on the long arm of chromosome 10 at 10q11.2 
(Minoletti et al. 1994). It encodes a 1845-bp coding sequence and a 70-kDa 
protein. It is ubiquitously expressed, so the RET/PTC3 activation is due to the 
specificity for the thyroid tissue of the somatic rearrangement of the ret proto-
oncogene.  
 NCOA4 protein contains a coiled-coil domain (amino acids 17-125) 
that mediates protein oligomerization (Monaco et al. 2001) and two motifs, 
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LxxLL (aa 92-96) and FxxLF (aa 328-332), that mediate binding to 
peroxisome-proliferator activated receptor gamma  (PPARgamma) and 
androgen receptor (AR), respectively (Fig. 5).  
 
   
 
Figure 5 - RFG protein structure. The N-terminal coiled coil domain mediates dimerization. 
The two motifs LxxLL and FxxLF, which determine the binding, respectively, to PPARgamma 
and Androgen Receptor (AR) are shown. The LLG motifs which are responsible for protein-
protein interaction are shown. The bold arrow indicates breakpoint in RET/PTC3. 
 
 
NCOA4 functions as a co-activator of several nuclear hormone 
receptors transcriptional activity, including AR and PPARgamma (Yeh et al. 
2002; Heinlein et al. 1999) (He 2002; Hsu 2003; Hu 2004; Miyamoto 1998; 
Lin 2002).  It is able to support AR transcriptional activation not only by 
androgens but also by other ligands like antiandrogens (hydroxyflutamide, 
bicalutamide, cyproterone acetate, and RU58841). Proteasome function is 
necessary for the interaction, since the proteasome inhibitor MG132 blocks AR 
localization to the nucleus and interaction with NCOA4 (Lin et al. 2002).  
NCOA4 protein levels have been found altered in several human 
tumours. Many reports have demonstrated that NCOA4 expression decreases 
during prostate tumorigenesis and that NCOA4 has a negative effect on growth 
and survival of prostate carcinoma cell lines (Tekur et al. 2001; Li et al. 2002). 
Moreover, it has been shown that around 50 % of invasive ductal carcinoma of 
the breast loses NCOA4 expression whereas the protein is present in normal 
mammary epithelium (Kollara et al. 2001).  
In order to identify additional roles of NCOA4 protein, in our lab a 
yeast two-hybrid screening has been performed using the NH2 terminal portion 
of NCOA4, the portion fused to RET in RET/PTC3, which contains the coil 
coiled domain. We isolated 10 different NCOA4-encoding clones, which 
confirmed that NCOA4 is able to form oligomers (Monaco et al. 2001), and 
two cDNA clones encoding the COOH-terminal portion (aa 576-719) of the 
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minichromosome maintenance 7 (MCM7) protein (Carlomagno et al. 
submitted). 
 
 
1.4 MINICHROMOSOME MAINTENANCE (MCM) PROTEINS AND 
DNA REPLICATION 
 
 
DNA replication is tightly regulated at the initiation step by both the 
cell cycle machinery and checkpoint pathways (Machida et al. 2005). 
In eukaryotic cells initiation of DNA synthesis occurs at defined sites 
(replication origins) scattered along the chromosome. Replication origins are 
bound by the origin recognition complex (ORC), which permits the recruitment 
of replication factors through a stepwise reaction leading to formation of 
replication forks, the functional units of DNA syhthesis (Bell and Dutta 2002; 
Mendez and Stillman 2003; Maiorano et al. 2006). 
Minichromosome maintenance proteins (MCM) were first identified in 
the yeast Saccaromyces cerevisiae as mutants defective in the maintenance of 
minichromosomes, suggesting a role in DNA replication. 
Six of them (MCM2-7) are related to each other and interact to form a stable 
heteroexamer in solution (Tye 1999; Kearsey and Labib 1998).     
MCM2-7 form a complex that plays a key role in licensing replication 
origins for DNA synthesis (Chong et al. 1995; Kubota et al.1995; Tanaka et al. 
1997; Yan et al.1993). Several studies demonstrated that MCM proteins are 
able to unwind DNA, functioning as the helicase of the replication fork (Labib 
et al. 2000; Lee and Hurwitz 2000; You et al. 1999; Pacek et al. 2004; Labib 
and Diffley 2001).  
They are recruited to DNA replication origins in a highly regulated reaction at 
mitosis exit, leading to formation of the pre-replicative complex (pre-RC) (Bell 
and Dutta 2002). MCM proteins bind to chromatin in a cell cycle-dependent 
manner, being tightly bound in late mitosis and G1 and being removed in S- and 
G2-phases (Kearsey and Labib 1998). This regulation is crucial to restrict 
replication of chromosomes to only one round per cell cycle (Maiorano et al. 
2006). 
In fact, the replication origins can switch between two chromatin states : a pre-
replication state (pre-RC), when the MCM complex is localized at replication 
origins; and a post-replication state (post-RC), when the MCM complex is 
delocalized from replication origins (Diffley et al. 1994). 
 The pre-RC assembly starts with the binding of six-subunit origin 
recognition complex (ORC) to specific origin sites on DNA (Quintana and 
Dutta 1999). ORC binding allows the additional binding of initiation factors 
during a cascade of protein assembly that finally results in the formation of 
pre-RC (Fig. 6). 
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Figure 6 - Assembly of the pre-replication complex. Once ORC recognized the specific 
origin sites on DNA, it allows the other initiation factors to bind in highly specific manner. 
Cdc6 binds to ORC, then Cdt1 is recruited to the origin allowing the MCM2-7 binding. The 
G1-S phase cdks phosphorylates Cdc6, which is released and Cdc45 binds to the licensed 
origin. Replication bubble is formed by activation of MCM2-7 helicase and recruitment of RPA 
and Primase-Polα occurs. 
 
 
In particular, in early G1, the Cdc6 protein functionally interacts with ORC and 
loads Cdt1, which in turn recruits the MCM proteins (MCM2-7). The assembly 
of ORC, Cdc6, Cdt1 and MCM proteins into pre-RC makes chromatin 
competent or licensed for replication (Chevalier and Blow 1996). Loading of 
MCM2-7 complex is also regulated by the geminin protein, which binds to 
Cdt1 onto chromatin (Maiorano et al. 2004; Kulartz and Knippers 2004) and 
thereby blocks the interaction of Cdt1 with MCM2-7 (Lee et al. 2004; Saxena 
et al. 2004). Moreover, geminin may also contribute to pre-RC formation by 
stabilizing Cdt1 in G2/M phases (Ballabeni et al. 2004). At G1 to S phase 
transition, DNA replication is initiated by concerted action of S phase-
promoting cyclin-dependent kinases and the Dbf4-dependent Cdc7 kinase 
(Pasero and Schwob 2000; Sclafani 2000). This event is referred to as “origin 
firing”. Cdc6 is phosphorylated and released together with Cdt1. Other 
replication factors as CDC45 and GINS complex bind to licensed origin. 
Activation of MCM2-7 helicase function is turned on by these new factors and 
induces opening of the replication bubble, allowing loading of the single strand 
binding protein RPA and Polα-Primase, which synthetizes the RNA/DNA 
primer. The primer is recognized by RFC, the clamp loader, which recruits in 
turn PCNA, the processivity factor of DNA polymerases. PCNA allows the 
polymerase switching to occur and DNA pol α is replaced by DNA pol δ and 
DNA pol ε, which display greater processivity and have proofreading 
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exonuclease activity (Ritzi and Knippers 2000). At each replication bubble the 
replication starts and proceeds bidirectionally with the helicase walking ahead 
of the fork to generate single strand and DNA polymerases elongating the 
nascent DNA in 5’-3’ direction. The MCM proteins gradually dissociate from 
chromatin as S phase proceeds (Krude et al. 1996) and replication forks merge,  
consistent with their predicted function as a DNA helicase (Ishimi 1997). 
  
1.5 MCM PROTEINS AND CANCER 
 
 
Because of its vital role in genome duplication in proliferating cells, 
deregulation of the MCM function results in chromosomal defects that may 
contribute to tumorigenesis. The MCM proteins are highly expressed in 
malignant human cancer cells and pre-cancerous cells undergoing malignant 
transformation. They are not expressed in differentiated somatic cells that have 
been withdrawn from the cell cycle. Indeed in human cells, MCM proteins 
have recently emerged as an important biomarker for growth and 
carcinogenesis. A strong correlation has been observed between entry in 
quiescent, differentiated or senescent state and downregulation of MCM 
proteins (Blow et al. 2002; Stoeber et al. 2001). In fact, deregulation of 
MCM2-7 appears to be an early event in tumorigenesis in a range of different 
tumor types and has led to recent development of human MCM antibodies as 
diagnostic tools for common carcinomas (Stoeber et al. 1999; Williams et al. 
1998; Stoeber et al. 2002; Meng et al. 2001; Laskey 2005). 
MCM proteins are overexpressed in many types of human tumour 
including colorectal, oesophageal, ovarian, laryngeal, urothelial, vulval and 
thyroid cancers (Gonzalez et al. 2005; Guida et al. 2005). A gain of the 7q 
chromosomal region that includes MCM7 has been observed in prostate (Ren 
et al. 2006) and hypopharyngeal (Cromer et al. 2004) carcinomas. Finally, 
targeting of MCM7 expression to the basal layer of the epidermis in transgenic 
mice significantly increased the incidence of tumor development after two-
stage chemical carcinogenesis (Honeycutt et al. 2006). Thus, MCM proteins 
are believed to act as important players in the process leading to autonomous 
growth of neoplastic cells (Gonzalez et al. 2005).  
 
 
1.6 ANALYSIS OF NCOA4-MCM7 INTERACTION AND ITS 
FUNCTIONAL ROLE IN XENOPUS LAEVIS EGG EXTRACTS 
 
 
 An in vitro pull down assay performed using two NCOA4 recombinant 
proteins constituted by NUS tag (NUS) fused to full length NCOA4 protein 
(NUS-NCOA4) or to the NH2-terminal fragment of NCOA4 (amino acids 1-
238) [NUS-NCOA4(N)] confirmed NCOA4-MCM7 interaction. Both NUS-
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NCOA4 and NUS-NCOA4 (N), but not NUS moiety alone or empty beads, 
pulled down MCM7 protein from HeLa cells protein extracts (Fig. 7). 
 
 
Figure 7 - HeLa cell protein extract pull down assay. HeLa cell protein extract was 
subjected to an in vitro pull-down assay with the NUS, NUS-NCOA4 or NUS-NCOA4 (N) 
recombinant proteins in duplicate. Bound proteins were immunoblotted with anti-MCM7 and 
anti-MCM3 antibodies. HeLa cell total extract and the beads alone were used as a control. 
 
 
In order to investigate the functional role of NCOA4-MCM7 interaction with 
respect to DNA replication, we used Xenopus laevis cell-free DNA replication 
system. DNA replication can be reproduced in vitro using de-membranated 
sperm and extracts from Xenopus laevis eggs, containing all the components 
needed to replicate DNA (Murray 1991). Also in this system, we found that the 
recombinant protein NUS-NCOA4 (full length human NCOA4 fused to the 
NUS tag) was bound to the endogenous Xenopus MCM7 (MCM7). 
Exogenously added recombinant NUS-NCOA4, incubated with sperm DNA in 
activated Xenopus laevis egg extracts, inhibited DNA replication in a dose-
dependent manner by interacting with MCM7 protein. Interestingly, only the 
full length NCOA4 protein, but neither the isolated NCOA4 NH2-terminal 
fragment [NUS-NCOA4 (N)] (aa 1-238) nor the COOH-terminal fragment 
[NUS-NCOA4 (C)] (aa 239-614), blocked the DNA replication. 
In order to understand at what level DNA replication was hindered we 
analyzed DNA bound proteins by chromatin pull down experiments in which 
DNA loaded proteins were separated from unbound fraction by centrifugation 
on a sucrose gradient. In the presence of NUS-NCOA4, pre-RC components 
(such as Cdc6 and MCM7) were not affected in their binding to DNA; neither 
CDC45 protein binding was decreased while PCNA binding was strongly 
reduced. Therefore, we hypothesized that NCOA4 might hinder late steps of 
DNA replication. One possibility was that NCOA4 inhibited DNA unwinding, 
a step secondary to CDC45 loading and preceding primer synthesis, PCNA 
loading and DNA elongation (Bell et al. 2002; Pacek et al. 2006; Labib et al. 
2000; Takayama et al. 2003). To address this question, we measured 
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aphidicolin-induced hyperloading of replication protein A (RPA) in the 
presence of NCOA4. Aphidicolin is a DNA polymerase inhibitor that 
uncouples DNA unwinding from DNA polymerization, thereby generating 
long stretches of single-strand DNA that is rapidly covered by the single-strand 
binding protein RPA. Therefore, aphidicolin-induced hyperloading of RPA is a 
bona fide measurement of replicative DNA helicase activity. NUS-NCOA4 
inhibited aphidicolin-induced RPA hyperloading, which indicates that it was 
blocking DNA unwinding. Again, NCOA4 did not affect MCM7 binding to 
DNA. NCOA4-induced reduction of RPA loading on chromatin was almost 
undetectable in the absence of aphidicolin, probably because this loading is 
very low during unperturbed DNA synthesis. The association of 
Primase/DNApol α to chromatin, which is strictly dependent on origin 
unwinding (Walter et al. 2000), was greatly reduced by 150 nM NUS-NCOA4. 
This accounts for the absence of PCNA loading. Finally, NCOA4 did not affect 
the replication of a circular single-strand DNA template derived from the M13 
bacteriophage, a process that occurs independently of replicative DNA helicase 
(Cox et al. 1990; Jenkins et al. 1992; Carlomagno et al. submitted). 
By generating an affinity-purified anti-XNCOA4 antibody able to 
immunoprecipitate in vitro-translated XNCOA4 and an endogenous protein 
from egg extracts that had the same molecular weight as in vitro-translated 
XNCOA4, we were able to demonstrate that the endogenous XNCOA4 and 
MCM7 proteins formed a complex in egg extracts, independently of the 
presence of chromatin.  
Immunodepletion of endogenous XNCOA4 augmented DNA synthesis by 
increasing DNA unwinding, as shown by RPA increased loading. In parallel, 
PCNA chromatin binding was enhanced whereas MCM7 and CDC45 
chromatin loading remained unchanged. As a control, the addition of 
exogenous NUS-NCOA4 to XNCOA4-depleted extracts restored normal levels 
of both DNA replication and PCNA loading (Carlomagno et al. submitted).  
These data indicated that in Xenopus laevis egg extracts NCOA4 functions as a 
novel regulator of DNA replication by modulating MCM2-7 helicase activity. 
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2.   AIMS OF THE STUDY 
 
 
 
 In papillary thyroid carcinoma (PTCs), NCOA4 is frequently targeted 
by chromosomal rearrangements that cause fusion of NCOA4 5’ portion to the 
TK encoding exons of RET generating the RET/PTC3 chimeric gene. The best 
described role for NCOA4 in the rearrangement is to drive RET/PTC3  
expression and its dimerization, activating RET enzymatic function in a 
constitutive manner in thyroid cells. It could not be excluded, though, that 
inactivation of NCOA4 function contributed to tumorigenesis as well. 
We demonstrated that NCOA4 is a negative controller of DNA replication in 
Xenopus laevis egg extracts. Thus, by interacting with MCM7, NCOA4 hinders 
MCM2-7 helicase activity and blocks DNA unwinding which generates single 
strand DNA that function as template for processive DNA polymerases. 
 Aim of this study is to analyse the role of NCOA4 protein in 
mammalian cells. We used as a model system HeLa cells to: 
1. investigate in which cellular compartment NCOA4 protein is located 
and interacts with MCM7 
2. study regulation of NCOA4 protein levels in different cell cycle phases 
3. investigate the role of NCOA4 in controlling DNA replication in 
mammalian cells by modulating its protein levels by use of TET-on 
inducible system and RNAi oligonucleotides. 
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3.   MATERIALS & METHODS 
 
 
 
3.1  RECOMBINANT PROTEINS  
 
 
 NUS-NCOA4 and NUS-NCOA4(N) were generated by PCR 
amplification of the entire NCOA4 ORF or its 5’-terminal (amino acids 2-238) 
portions, respectively. Fragments were then fused in-frame to the solubility tag 
NusA in the pET vector. The plasmids were controlled by DNA sequencing. 
Recombinant proteins were produced in Escheria coli by using standard 
protocols.  
 
 
3.2  PROTEIN STUDIES 
 
 
 Proteins were extracted according to standard procedures. 
 Cells were lysed in a buffer containing 50 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5), 1% 
(vol/vol) Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM 
sodium pyrophosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulphonyl 
fluoride (PMSF) and 1 μg/ml aprotinin. Lysates were clarified by 
centrifugation at 10,000 x g for 15 min. Lysates containing comparable 
amounts of proteins, estimated by a modified Bradford assay (Bio-Rad, 
Munchen, Germany), were immunoprecipitated with the required antibody or 
subjected to direct western blot. Immune complexes were detected with the 
enhanced chemiluminescence kit (Amersham Pharmacia Biotech). For binding 
assay (pull-down), HeLa cells lysates were incubated with 5 μg of immobilized 
fusion proteins. Bound proteins were detected by immunoblot analysis. 
For fast protein liquid chromatography (FPLC), column was equilibrated in 50 
mM sodium phosphate buffer pH 7.0 containing 0.15 M NaCl, and used at a 
flow rate of 0.3 ml/min. One mg of HeLa cell protein extract was loaded on the 
column and 30 fractions of 1 ml each were collected. The last 14 fractions were 
selected for TCA precipitation, re-suspended in 1X Laemmli buffer and run on 
a 10% SDS-PAGE. Immunoblotting was carried out with specific antibodies. 
 
 
3.3  CELL FRACTIONATION AND ANALYSIS OF NUCLEAR 
FRACTIONS 
 
 
For subcellular fractionation, cells in the mid-exponential phase of 
growth were collected by scraping from the culture dish after two washings 
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with 20 ml ice-cold 1X phosphate-buffered saline (PBS). Cell pellets were 
collected by centrifugation at 6,000 x g for 2 min in a refrigerated microfuge. 
The pellet was re-suspended in 5 packed cell volumes (PVC) of buffer A (10 
mM HEPES-KOH pH 7.6, 1.5 mM MgCl2, 10 mM KCl , 0.5 mM DTT and 
protease inhibitor cocktail) and swollen for 10 min. The cell suspension was 
transferred to a 1-ml Dounce homogeniser. Cells were broken by 40 strokes 
and nuclei were pelleted by centrifugation at 2,800 x g. The nuclear pellet was 
re-suspended in 0.9 volumes of buffer C (0.1 % Triton X-100, 20 mM HEPES-
KOH pH 7.9, 25% (v/v) glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 0.5 mM DTT, protease inhibitor cocktail). The suspension was frozen 
and thawed three times and then nuclear debris was pelleted by centrifugation 
at 10,000 x g for 30 min in a cooled microfuge. 
Triton X-100-extracted nuclei were prepared as follows. Cells cultured 
in 100-mm dishes were washed three times with ice-cold phosphate-buffered 
saline and divided in three aliquots. One aliquot was lysed with standard 
buffer (total) as described above. Two aliquots were incubated separately 
for 10 min on ice with 200 ml of ice-cold CSK buffer (10 mM PIPES, pH 6.8, 
100mM NaCl, 300 mM sucrose, 1mM MgCl2, 1 mM EGTA, 1 mM DTT, 1 
mM phenylmethylsufonyl fluoride, 10 mg/ml aprotinin) containing 0.5% 
Triton X-100 (Pierce Biotechnology, Rockford, Il). Chromatin bound proteins 
were separeted from unbound proteins by low speed centrifugation (3,000 rpm, 
3 min at 4°C). One of the two pellets was further digested with 1,000 units/ml 
DNase I (10 units/ml, RNase-free, Boehringer Mannheim, Germany) in 100 ml 
of  0.5%Triton X-100 containing CSK supplemented with 1mM ATP at 25° C 
for 30 min. Samples were analysed by SDS-PAGE upon loading equivalent 
amounts for each fraction (Fujita et al. 1997). 
 
 
3.4  CELL CULTURE METHODS, IMMUNOFLUORESCENCE AND 
CYTOFLUORIMETRIC ANALYSIS 
 
 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (Invitrogen Groningen, The 
Netherlands).  
The human NCOA4 full-length cDNA was cloned in pcDNA/TO/myc-HIS 
(Invitrogen) and stably transfected in HeLa T-Rex cells containing the Tet 
repressor under the control of the CMV promoter (Invitrogen). Marker-selected 
cell clones were isolated and characterized for NCOA4 expression by 
immunoblot. Two clones (clone 23 and 24) were selected for further studies. 
Anti-NCOA4 si RNAs were designed with a program available online 
(http://jura.wi.mit.edu/siRNAext) and synthesized by Proligo (Boulder, CO).  
Primers sense strands were: 
NCOA4 1i: 5’-UAUCUCCAUGCCAGAGCAGAA-3’ 
NCOA4 2i: 5’-AAGAUUCAACUGUCCUGCUCUUU-3’ 
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NCOA4 3i: 5’- GGCCCAGGAAGUAUUACUU-3’ 
Scrambled: 5’-ACCGUCGAUUUCACCCGGUU-3’ 
Transfection was performed with 100 nM of siRNA using the oligofectamine 
reagent (Invitrogen). 
For the double-thymidine block, cells were treated for 12-14 h with 
complete medium containing 2 mM thymidine, released in 24 µM cytidine for 
9 hours and retreated with 2 mM thymidine for a further 12-14 h. Upon 
thymidine wash-out, cells were harvested at different time points and processed 
for flow cytometry or immunoblot. Nocodazole arrest was performed by 
treating cells with 200 ng/ml nocodazole for 16 h. MG132 was used at a 50 μM 
final concentration starting from a 50 mM stock solution. Thymidine, Cytidine 
and Nocodazole were from Sigma Chemical Co.; MG132 was from 
Calbiochem. 
 For DNA synthesis measurements, cells were seeded on glass 
coverslips. Bromodeoxyuridine (BrdU; Sigma Chemical Co.) was added to the 
cell culture medium at a final concentration of 100 μg/ml for 1 h before 
harvest. Cells were fixed with paraformaldehyde (4%) and permeabilized with 
Triton X-100 (0.2%) before staining. Coverslips were incubated with anti-
BrdU mouse monoclonal antibody and then with a Texas red-conjugated anti-
mouse antibody (Boehringer Mannheim, Germany). All coverslips were 
counterstained in PBS containing Hoechst 33258 (final concentration, 1μg/ml; 
Sigma Chemical Co.), rinsed in PBS and mounted in Moviol on glass slides. 
The fluorescent signal was visualized with an epifluorescent microscope 
(Axiovert 2, Carl Zeiss, Göttingen, Germany) interfaced with the image 
analyzer software KS300 (Carl Zeiss). For PCNA foci detection, HeLa cells 
were seeded on glass coverslips, fixed in 4% paraformaldehyde in PBS and 
blocked in PBS containing 1% BSA, 0.1%Triton X-100 and 0.02% SDS. 
Primary and secondary antibodies were diluted in the same blocking buffer. 
Anti-PCNA antibody was PC-10 from Calbiochem. FITC-stained secondary 
anti-mouse antibody was from Molecular Probes (Invitrogen). Stained cells 
were observed with a Zeiss LSM 510 META confocal microscope (Zeiss, 
Gottingen, Germany). For cytofluorimetric analysis, cells were harvested when 
subconfluent, fixed in 80% ethanol for 1 h at -20°C, rehydrated in PBS, and 
then treated with RNase A (100U/ml) for 30 min.  
Propidium iodide (50 µg/ml) was added to the cells for 30 minutes in the dark.  
Samples were analysed with a CYAN flow cytometer (Dako Corporation, San  
Jose, CA, USA) using an argon-ion laser tuned to 488nm measuring forward 
and orthogonal light scatter, and red fluorescence measuring area and either 
peak of the fluorescent signal. Data were acquired using SUMMIT® software 
and analysed with Modfit® software. 
For PCNA foci detection, HeLa cells were seeded on glass coverslips, 
fixed in 4% paraformaldehyde in PBS and blocked in PBS containing 1% 
BSA, 0.1%Triton X-100 and 0.02% SDS. Primary and secondary antibodies 
were diluted in the same blocking buffer. Anti-PCNA antibody was PC-10 
from Calbiochem. FITC-stained secondary anti-mouse antibody was from 
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Molecular Probes (Invitrogen). Stained cells were observed with a Zeiss LSM 
510 META confocal microscope (Zeiss, Gottingen, Germany). For 
cytofluorimetric analysis, cells were harvested when subconfluent, fixed in 
80% ethanol for 1 h at -20°C, rehydrated in PBS, and then treated with RNase 
A (100U/ml) for 30 min.  
 
 
3.5  CHROMATIN IMMUNOPRECIPITATION 
 
 
Chromatin immunoprecipitation was performed from exponentially 
growing HeLa cells using preimmune serum and purified anti-NCOA4 and 
anti-RPA antibodies, using ChIP assay Kit (Upstate Biotechnology, Millipore 
Corporate). 
 Primers for PCR we as follows: 
Lamin B2 origin: 
Forward 5’-GGCTGGCATGGACTTTCATTTCAG-3’ 
Reverse 5’-GTGGAGGGATCTTTCTTAGACATC-3’ 
Control region:  
Forward 5’-CTGCCGCAGTCATAGAACCT-3’ 
Reverse 5’-ATGGTCCCCAGGATACACAA-3’ 
 
c-Myc origin:  
Forward 5’-TATCTACACTAACATCCCACGCTCTG-3’ 
Reverse 5’-CATCCTTGTCCTGTGAGTATAAATCATCG-3’ 
Control region:  
Forward 5’-TTCTCAACCTCAGCACTGGTGACA-3’ 
Reverse 5’-GACTTTGCTGTTTGCTGTCAGGCT-3’ 
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4.   RESULTS AND DISCUSSION 
 
 
 
4.1 NCOA4 AND MCM7 INTERACT IN THE NUCLEUS IN HeLa 
CELLS 
 
Initially, we analysed in which cellular compartment NCOA4 protein was 
located in HeLa cells. MCM7 is prevantly a nuclear chromatin bound protein, 
even if its overexpression in cancer cells often causes an accumulation of the 
protein also in the cytosolic compartment. 
In sub-cellular fractionation experiments, NCOA4 and MCM7 appeared in 
both the cytoplasmic and nuclear compartments (Fig. 8).  
 
 
 
Figure 8 - NCOA4 cellular localization. NCOA4 cytosolic (C) and nuclear (N) fractions of 
HeLa cells were immunoblotted with anti-NCOA4 and anti-MCM7 antibodies. Total (T) 
protein extract was loaded as a control. Anti SP1 (nuclear) and anti SHC (cytosolic) 
antibodies served to verify the purity of the fractions. 
 
 
Moreover, like MCM7 (Bell et al. 2002), NCOA4 was present in the chromatin 
bound Triton X-100 (0.5%) insoluble fraction, and DNAse treatment was able 
to solubilize both NCOA4 and MCM7 from chromatin (Fig. 9).  
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Figure 9 - NCOA4 is bound to chromatin. 0.5% Triton X-100 soluble (S) and insoluble (P) 
fractions, and proteins solubilized upon DNAse treatment from HeLa cells were immunoblotted 
with anti-MCM7 and anti-NCOA4 antibodies. 
 
 
Anti-NCOA4 antibody was able to co-immunoprecipitate MCM7 protein, 
indicating interaction of the two proteins at the endogenous level. MCM6 and 
MCM5 proteins were also present in the complex (data not shown), suggesting 
that NCOA4 interacts with MCM7 in the context of the entire MCM2-7 
complex. This was also confirmed by a gel-filtration experiment, in which 
NCOA4 co-eluted with the MCM2-7 protein complex in a fraction whose 
apparent molecular mass was ∼600 kDa, confirming that the protein was 
interacting with the entire complex (Fig. 10).  
 
 
 
Figure 10 – NCOA4 interacts with the entire complex MCM2-7. HeLa protein extract was 
loaded on a fast protein liquid chromatography column and 14 sequential fractions (1-14) 
were collected. Western blotting of each fraction was performed with the indicated antibody. 
The calibration molecular mass curve is indicated. 
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Using HeLa sub-cellular fractions, we observed that NCOA4–MCM7 
interactions was confined to the nucleus and occurred preferentially on 
chromatin (Fig. 11), even if the amount of NCOA4 in the nucleus is lower than 
in the cytosol.  
 
 
 
 
Figure 11 - NCOA4 and MCM7 interaction takes place in the nucleus and on chromatin. 
Cellular fractions of HeLa cells were immunoprecipitated with anti-NCOA4 antibody, in order 
to identify where the NCOA4-MCM7 interaction takes place. Immunoblot with anti MCM7 and 
anti-NCOA4 was performed. Total protein extract was loaded as control.  
 
 
4.2 NCOA4 PROTEIN BINDS TO DNA REPLICATION ORIGINS IN 
HeLa CELLS 
 
 
 NCOA4 was already known to bind chromatin, functioning as a 
coactivator of nuclear receptor (Yeh et al. 2002; Heinlein et al. 1999) (He 
2002; Hsu 2003; Hu 2004; Miyamoto 1998; Lin 2002). We ought to investigate 
whether the protein was loaded on DNA replication origins as well by 
Chromatin Immunoprecipitation assay (ChIP). We chose two canonical 
replication origins, Lamin B2 and c-Myc. 
 NCOA4 was present at both Lamin B2 (Fig. 12A) and c-Myc (Fig. 
12B) origins. RPA protein was located at the same origins while neither 
proteins binding occurred on control region located several kb far apart 
(Dominguez-Sola et al. 2007) (Fig. 12). 
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Figure 12 - Chromatin immunoprecipitation at DNA replication origins located on 
human Lamin B2 (LB2) (A) and c-Myc (B) loci. Immunoprecipitation was performed using 
preimmune serum or anti NCOA4 and anti-RPA antibodies. Upper: maps depicting the 
location of relevant regions of the two loci. PCR fragments at origins and control regions are 
indicated. Lower: ethidium bromide staining of PCR products. 
 
 
4.3 NCOA4 PROTEIN LEVELS CHANGE DURING CELL CYCLE 
PHASES IN HeLa CELLS 
 
 
Proteins exerting functions associated to specific phases of cell cycle, 
such as control of DNA synthesis, often display fluctuation of protein levels 
along cell cycle progression. The classic example is represented by the 
negative regulator of pre-RC assembly, Geminin, whose concentration is high 
in S, G2 and early M phase in order to prevent re-licensing and re-replication 
but decreases at the beginning of G1 phase. 
To investigate whether NCOA4 protein levels were regulated during cell 
cycle, we arrested HeLa cells in phase G1/S (double-thymidine block) or M 
(nocodazole block). Cells were released from the block, proteins were 
harvested at different time points and NCOA4 protein levels measured by 
immunoblot. Geminin and cyclin B1 were used as a control of proteins whose 
levels chage during cell cycle while tubulin was used for normalization. Cell 
cycle progression was monitored with cytofluorimetric analysis.  
NCOA4 protein levels were low in late G1 and in S, progressively 
increased in G2 and peaked at the M to G1 transition (Fig. 13A, B). 
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Figure 13 - NCOA4 protein levels during cell cycle phases. Upon release from double-
thymidine (A) or a nocodazole (B) block, NCOA4 protein levels were measured at the 
indicated time points by immunoblot. Flow cytometry and immunoblotting for Cyclin B1 
(cycB1) and Geminin were used to monitor cell cycle progression; tubulin was used for 
normalization.  
 
 
Consistently, also in Xenopus laevis egg extracts, endogenous XNCOA4 
levels decreased upon initiation of DNA synthesis (data not shown). 
The decrease of NCOA4 levels during G1 phase of HeLa cells was caused by 
proteasome-mediated proteolysis being prevented by the proteasome proteases 
inhibitor, MG132 (Fig. 13B). 
 
 
4.4 NCOA4 PROTEIN AFFECTS CELL GROWTH AND DNA 
SYNTHESIS RATE IN HeLa CELLS 
 
 
In order to investigate the role played by NCOA4 protein in mammalian 
cells, we investigated the effect of modulating protein levels in HeLa cells. 
HeLa cells were transiently transfected with three different NCOA4 
small inhibitory duplex RNAs (NCOA4 1i, 2i and 3i) and DNA synthesis was 
measured by Bromodeoxyuridine (BrdU) incorporation. 
NCOA4 siRNAs, but not the scrambled control, increased DNA synthesis, 
measured as incorporation of BrdU, at both 48 and 72 hours. 
This effect was more pronounced with NCOA4 2i, than with NCOA4 1i and 3i, 
which is in line with its stronger capacity to knock down NCOA4 protein 
levels (Fig. 14A and C). 
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Figure 14 – Interference with NCOA4 protein increases DNA replication. HeLa cells were 
mock-transfected (-) or transfected with NCOA4 2i or NCOA4 3i siRNAs or scrambled siRNA. 
After 48 and 72 hour. NCOA4 protein levels were measured by immunoblotting. Anti lamin 
antibody was used for normalization (A and C). DNA synthesis was measured by anti-BrdU 
immunofluorescence (B and D). The average results ± SD of three independent experiments 
made in duplicate are reported. 
 
 
 Moreover, in a G1/S synchronized cell population (double–thymidine 
block), NCOA4 2i siRNA increased DNA synthesis rate by accelerating entry 
in S phase. As shown in fig. 15, scrambled transfected cells, once released 
from the block, took one hour to enter in S phase, whereas NCOA4 2i cells 
moved in S phase in 20 min. The increased rate of DNA synthesis (amount of 
synthesized DNA in a time lapse) suggests that NCOA4 might be involved in a 
locking mechanism to keep either extra or late firing origins blocked so that, 
when decreased, the cell activates more origins simultaneously. 
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Figure 15 - Cytofluorimetric analysis of synchronized HeLa cells. Scrambled or NCOA4 2i 
transfected cells were released from double-thymidine block for the indicated time points and 
subjected to cytometry. Percentage of cells in G1, S and G2 phases is indicated. 
 
 
Therefore to exclude that NCOA4 interfered cells increased DNA replication 
rate was due to increased licensing of origins but rather to increased activity of 
the fork in later steps of DNA replication, we analyzed MCM7 and PCNA 
loading onto chromatin. As already discussed MCM7 binding to DNA is a 
measure of the number of licensed origins while PCNA loading depends on the 
quantity of activated origins upon firing. 
In NCOA4-interfered HeLa cells, the increased DNA synthesis was paralleled 
by augmented recruitment of PCNA to chromatin whereas the chromatin-
bound fraction of MCM7 protein remained unchanged (Fig. 16). 
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Figure 16 - MCM7 and PCNA chromatin binding in NCOA4 interfered HeLa cells. Total, 
0.5% Triton X-100 soluble and insoluble fractions, as well as soluble and insoluble fractions of 
the DNAse-extracted insoluble aliquots (P+DNase) from scrambled RNAi or NCOA4 2i 
transfected cells were immunoblotted with anti MCM7 and anti-PCNA antibodies 
 
 
These data were consistent with our findings obtained in the Xenopus 
laevis model system (Carlomagno et al. submitted), where increased DNA 
synthesis was paralleled by augmented recruitment of PCNA to chromatin 
whereas the chromatin-bound fraction of MCM7 protein remained unchanged, 
and confirmed that, also in HeLa cells, NCOA4 does not control origin 
licensing but later steps of origin activation (Fig. 16). 
Lastly, we investigated the effects of adoptive NCOA4 overexpression. 
Cells were engineered to express NCOA4 under the control of a doxycycline-
inducible promoter. We were able to obtain a 1-fold induction of protein 
expression in two different clones, clone 23 and clone 24 (Fig. 17). 
 
 
Figure 17 - NCOA4 doxycycline-induced expression. Immunoblot detection of Myc-tagged 
NCOA4 protein upon doxycycline (Dox) (48 hours) induction in two independent HeLa-NCOA 
clones (clones 23 and 24). 
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Induction of NCOA4 protein decreased cell growth, as shown in Fig. 18, 
more efficiently in clone 24 then in clone 23. 
 
 
 
 
 
 
Figure 18 - NCOA4 negatively affects cell growth. HeLa-NCOA4 (clones 23 and 24) cell 
growth with and without Doxycycline; the average results ± SD of three independent 
experiments performed in triplicate are reported. 
 
 
In order to understand the mechanism lying behind such arrest, we 
measured DNA synthesis as incorporation of BrdU (Bromodeoxyuridine) 
measured by immunofluorescence staining with an anti-BrdU antibody. 
NCOA4 doxycycline-induction determined a reduced BrdU incorporation. It 
also caused cells to accumulate in S phase probably consequent to a reduced 
rate of DNA synthesis, as shown in fig. 19. 
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Figure 19 - HeLa-NCOA4 cells flow cytometry and anti-BrdU immunofluorescence upon 
Doxycycline treatment (48 hours). The average results ± SD of three independent 
experiments made in duplicate are reported. *P< 0.02 (two-side paired Student’s t-test). The 
same results were obtained with HeLa-NCOA4 clone 23 (not shown).  
 
 
Decrease in BrdU incorporation with an increase in S-phase cells in an 
asynchronous cell population indicated that cells were able to enter S phase but 
were slowed down due to a hindrance of DNA synthesis, consistently with data 
obtained in Xenopus laevis  egg extracts and in NCOA4 interfered cells.  
Finally, we analyzed MCM7, RPA and PCNA chromatin binding to 
chromatin upon induction of NCOA4 protein. NCOA4 overexpression 
determined a reduced RPA and PCNA loading onto chromatin, while MCM7 
binding remained unchanged. These data confirmed the hypothesis that DNA 
replication origins licensing was not affected by increased levels of NCOA4 
protein, while DNA unwinding and therefore synthesis was strongly decreased 
(Fig. 20).  
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Figure 20 - MCM7 and PCNA chromatin binding in NCOA4-overexpressing HeLa cells 
(A) Total, 0.5% Triton X100 soluble (S) and insoluble (P) fractions, as well as soluble and 
insoluble fractions of the DNAse-extracted insoluble aliquots (P + DNAse) of HeLa NCOA4-
Cl24 cells treated or not with Dox for 48 hours were immunoblotted with anti-MCM7 and anti-
PCNA antibodies. (B) Laser confocal microscopy of cells stained with anti-PCNA antibody. 
The same results were obtained with HeLa-NCOA4 clone 23 (not shown). 
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5.   CONCLUSIONS 
 
 
 
 Here we identified a novel protein network involving NCOA4 (a gene 
fused to the RET tyrosine kinase receptor in papillary thyroid carcinoma) and 
MCM7 (a component of the MCM complex essential for DNA synthesis). 
Based on our findings, we propose NCOA4 as a novel DNA replication 
inhibitor. Indeed NCOA4 interacts with MCM7 at the endogenous level in 
HeLa cells. This interaction is localized on DNA where MCM2-7 complex is 
functionally active at licensing DNA replication origins and unwinding DNA. 
Moreover, NCOA4 protein is loaded on canonical origins such as c-Myc and 
Lamin B2. Modulation of NCOA4 protein levels affects both cell growth and 
DNA replication rate by acting on later steps of DNA replication initiation, 
such as DNA unwinding. 
To our knowledge, this is the first example of a DNA replication 
controller that modulates origin unwinding, which wasn’t known to be a 
tunable step of DNA replication associated events. Moreover, the two proteins 
involved in this network, MCM7 and NCOA4, are frequently deregulated in 
tumors by either genetic or epigenetic events that induce changes in expression 
levels, invocating their involvement in the process of tumorigenesis. 
We postulate that chromosomal rearrangements that target the NCOA4 
gene in thyroid cancer might release MCM7 mitogenic activity from the 
negative control exerted by NCOA4. Thus, NCOA4 N-terminal fragment is a 
loss of function mutant incapable of blocking DNA replication in Xenopus 
laevis egg extracts. In this context, the NCOA4 N-terminal rearrangement 
might represent a novel paradigm of a cancer-associated chromosome 
rearrangement that directly targets a gene that controls cell proliferation. 
Moreover we cannot exclude that the RET/PTC3 chimeric protein displays 
dominant negative effect on the residual NCOA4 wild type protein encoded by 
the NCOA4 allele that is left untouched by the rearrangement. Indeed, it was 
demonstrated that RET/PTC3 heterodimerizes with wt NCOA4 via its coiled-
coil domain. The dominant negative role of NCOA4-RET fusion protein might 
be exerted by different possible mechanisms such as by localizing it to 
different cellular compartments or competing with MCM7 for interaction. 
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Context: Anaplastic thyroid carcinomas (ATC) are among the most
aggressive humanmalignancies and are characterized byhighmitotic
activity. Minichromosome maintenance proteins (MCM) 2–7 are re-
quired to initiate eukaryotic DNA replication, and their overexpres-
sion has been associated with dysplasia and malignancy.
Objective: In an attempt to cast light on the mechanisms governing
ATC, we evaluated MCM5 and MCM7 expression in human normal,
papillary (PTC), and anaplastic thyroid samples, aswell as in primary
culture cells and transgenic mouse models.
Results:MCM5 and MCM7 expression was high in 65% of ATC and
negligible in normal thyroid tissue and papillary thyroid carcinomas.
In ATC, high MCM5 and MCM7 expression was paralleled by high
levels of MCM2 and MCM6. An analysis of human ATC primary cell
cultures and of a transgenic mouse model of ATC confirmed these
findings. An increased transcription rate accounted for MCM7 up-
regulation, because the activity of theMCM7promoterwasmore than
10-fold higher in ATC cells comparedwith normal thyroid cells. Adop-
tive overexpression of wild-type p53, but not of its inactive (R248W
andR273H)mutants, strongly down-regulated transcription from the
MCM7promoter, suggesting that p53 knock-out contributes toMCM7
up-regulation in ATC. Treatment with small inhibitory duplex RNAs,
which decrease MCM7 protein levels, reduced the rate of DNA syn-
thesis in ATC cells.
Conclusion: MCM proteins are overexpressed in ATC and sustain
the high proliferative capacity of ATC cells. (J Clin Endocrinol
Metab 90: 4703–4709, 2005)
WELL-DIFFERENTIATED THYROID carcinomas(WDC) account for more than 90% of all thyroid
cancers and include papillary (PTC) and follicular (FTC)
carcinomas (1). Undifferentiated or anaplastic thyroid car-
cinomas (ATC) are highly malignant tumors and account for
less than 2–5% of all thyroid cancers. Despite its rarity, more
than half of the deaths attributed to thyroid cancer result
from ATC (2). ATC is usually seen in the sixth to seventh
decades of life (2, 3). Almost all ATC patients present with
a rapidly enlarging neck mass and frequently have evidence
of distant metastases in lung, bone, or brain at diagnosis (2,
3). More than 25% of ATC patients show coincidentally de-
tected WDC on histological examination, suggesting that, at
least in some cases, ATCmay derive from a preexistingWDC
(1–3).
Differently fromWDC, ATC have a high proliferation rate
and marked genetic instability. This is reflected in the rapid
tumor growth and dissemination that characterize the clin-
ical course of ATC. The combination of a short cell-doubling
time and a low apoptotic rate results in one of the most rapid
growth rates in any solid tumor, and ATC tumors may dou-
ble in size within 1 wk (2, 3). The molecular mechanisms
underlying the anaplastic transformation of thyroid follicu-
lar cells are largely unknown. Structural rearrangements of
the receptor tyrosine kinases RET and TRKA (tyrosine ki-
nase), which are common in PTC, and of PPAR (peroxisome
proliferator-activated receptor ), typical of FTC, are rarely
seen in ATC (4). Point mutations in RAS small GTPases (5)
and in the BRAF (BRCA2-associated factor) serine/threonine
kinase have been detected in ATC (6), and, at variance with
WDC, ATC is associated with a high prevalence of p53 gene
mutations (7, 8). Mutations in -catenin are also frequent in
ATC (9). In general, ATC are characterized by a high degree
of aneuploidy and complex chromosomal alterations (10); in
particular, loss of 16p is common in ATC cell lines (11).
Minichromosome maintenance proteins (MCM2–MCM7)
are required for DNA replication in eukaryotic cells. They
were originally discovered in yeast and subsequently iden-
tified in Drosophila melanogaster, Xenopus laevis, mice, and
humans (12). MCM proteins form a heterohexamer that is
part of the prereplication complex (pre-RC). pre-RC factors
bind to chromatin in a highly ordered sequence that triggers
DNA synthesis. The process begins with the loading of the
origin recognition complex. Cdc6 (cell division control pro-
tein 6) is then recruited to the site, and this allows loading of
First Published Online May 17, 2005
Abbreviations: ATC,Anaplastic thyroid carcinomas; BrdU, bromode-
oxyuridine; FTC, follicular thyroid carcinomas;MCM,minichromosome
maintenance protein; PCNA, proliferating cell nuclear antigen; pre-RC,
prereplication complex; PTC, papillary thyroid carcinoma; siRNA, small
inhibitory duplex RNA; WDC, well-differentiated thyroid carcinomas.
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the MCM complex. As cells enter S-phase, Cdc6 is released
and other factors are loaded onto the replication origin to
initiate DNA synthesis. The process requires the S-phase-
specific kinases CDK2 (cyclin-dependent kinase)-cyclin E
and Dbf4 (DNA binding factor)-Cdc7. Dissociation of the
pre-RC from chromatin ensures that each region of DNA is
replicated only once during a single cell cycle (12). Being one
of the helicases involved in DNA unwinding at the replica-
tion forks, MCM proteins are required throughout DNA
elongation (13, 14).
The expression of MCM proteins depends on the prolif-
eration state of the cell. Quiescent and differentiated cells do
not express MCM, whereas proliferating cells and cells with
proliferation potential do (15). In normal or reactive tissues,
MCM expression is restricted to proliferative compartments.
In contrast, in dysplastic and malignant tissues, MCM pro-
teins are present in most cells, and their expression level
inversely correlates with the degree of tumor differentiation
(15). Uterine cervix, prostate, and esophageal dysplasia are
positive to anti-MCM antibodies, and staining increases in
neoplastic lesions (16–19). MCM assay has a high specificity
and sensitivity in detecting cancerous cells in feces (colorectal
carcinoma) and urine (bladder carcinoma) (20, 21).
We have investigated the expression of MCM proteins in
normal thyroid tissue, PTC, and ATC tumors in mice and
humans. We show that MCM2, MCM5, MCM6, and MCM7
are expressed at a high level in ATC, and that MCM7 is
involved in the proliferation of ATC cells.
Materials and Methods
Immunohistochemistry
Tumors were retrieved from the files of the Pathology Departments
of the Hospital Central de Asturias (Oviedo University, Asturias, Spain)
and the Hospital Clinico Universitario (Santiago de Compostela Uni-
versity, Galicia, Spain) and the Department of Oncology of the Univer-
sity of Pisa (Pisa, Italy). In all cases, the study protocols were approved
by the respective institutional review boards. Cases were chosen ran-
domly among those for whom detailed clinical and follow-up data were
available. For each case, the sex and age of the patient at diagnosis, tumor
size, extrathyroidal extension, vascular invasion, lymph node or distant
metastases, stage, and survival were recorded. Normal thyroid tissue
samples were also retrieved from the files of the Department of Oncol-
ogy of the University of Pisa. Sections of paraffin-embedded samples
were stained with hematoxylin and eosin for histological examination
to ensure that the samples fulfilled the diagnostic criteria (22). Formalin-
fixed and paraffin-embedded 3- to 5-m-thick tumor sections were
deparaffinized, placed in a solution of absolute methanol and 0.3%
hydrogen peroxide for 30 min, and treated with blocking serum for 20
min. The slides were incubated overnight with mouse monoclonal an-
tibodies againstMCM5 (MCA 1860; Serotec, Oxford, UK), MCM7 (141.2,
sc-9966; Santa Cruz Biotechnology, Santa Cruz, CA), or proliferating cell
nuclear antigen (PCNA) (MAB424; Chemicon, Temecula, CA). After
incubation with biotinylated antimouse secondary antibody for 15 min,
slides were stained with premixed avidin-biotin complex (Vectostain
ABC kits; Vector Laboratories, Burlingame, CA). Sections were devel-
oped for 5 min with 0.05% 3,3-diaminobenzidine tetrahydrochloride
(Dako, Carpinteria, CA) and 0.01% hydrogen peroxide in 0.05 m Tris-
HCl buffer (pH 7.6), counterstained with hematoxylin, dehydrated, and
mounted. Negative controls were performed in each case by incubating
tissue slides with preimmune serum.
Cell cultures
Primary cell cultures of normal thyroid (S11N and S63N), follicular
adenoma (HTU31 and HTU42), PTC (HTU56 and HT59), and ATC
(HTU8 and S11T) were kindly donated by F. Curcio (University of
Udine, Udine, Italy) and H. Zitzelsberger (Forschungszentrum fur Um-
welt und Gesundheit, Neuherberg, Germany). The ARO cell line was
established from a human ATC by Guy J. Juillard (University of Cali-
fornia, Los Angeles, Los Angeles, CA) (7). Cells were grown in RPMI
supplemented with 20% fetal bovine serum (Invitrogen, Paisley, PA), 2
mm l-glutamine, and 100 U/ml penicillin–streptomycin (Invitrogen).
For the measurement of MCM5 and MCM7 half-life, cells were grown
to subconfluence and then treatedwith 10g/ml cycloheximide (Sigma,
St. Louis, MO) for up to 48 h. For bromodeoxyuridine (BrdU) incorpo-
ration, cells were seeded on glass coverslips. Forty-eight hours after
transfection, BrdU (Sigma) was added to the cell culture media at a final
concentration of 100 g/ml for 2 h before harvest. Cells were fixed with
paraformaldehyde (4%) and permeabilized with Triton X-100 (0.2%)
before staining. Coverslipswere incubatedwith anti-BrdUmousemono-
clonal antibody and then with a fluorescein isothiocyanate-conjugated
antimouse antibody (Roche Molecular Biochemicals, Mannheim, Ger-
many). Coverslipswere counterstained in PBS containingHoechst 33258
(final concentration, 1 g/ml; Sigma), rinsed in PBS, and mounted in
Moviol on glass slides. The fluorescent signal was visualized with an
epifluorescent microscope (Axiovert 2; Zeiss, Oberkochen, Germany)
interfaced with the KS300 image analyzer software (Zeiss).
Protein analyses
Protein lysates were prepared according to standard procedures.
Briefly, cells or tumor tissues were lysed in a buffer containing 50 mm
HEPES (pH 7.5), 1% (vol/vol) Triton X-100, 50 mm NaCl, 5 mm EGTA,
50 mm NaF, 20 mm sodium pyrophosphate, 1 mm sodium vanadate, 2
mm phenylmethylsulfonyl fluoride, and 1 g/ml aprotinin. Lysates
were clarified by centrifugation at 10,000  g for 15 min. Lysates con-
taining comparable amounts of proteins, estimated by a modified Brad-
ford assay (Bio-Rad,Munich, Germany), were subjected toWestern blot.
Immune complexes were detected with the enhanced chemilumines-
cence kit (Amersham Biosciences, Little Chalfont, UK). The image was
saved by the Typhoon 8600 laser scanning system (Amersham Bio-
sciences). The density and width of each band was quantified using the
ImageQuant 5.0 software (Amersham Biosciences). Anti-MCM2 (N-19;
sc-9839), anti-MCM6 (C-20; sc-9843), and anti-MCM7 (141.2; sc-9966)
were from Santa Cruz Biotechnology. Anti-MCM5 (MCA 1860) was
from Serotec. Anti--tubulin was from Sigma. Secondary antibodies
coupled to horseradish peroxidasewere fromSantaCruz Biotechnology.
Triton X-100-extracted nuclei were prepared as described previously
(23). Briefly, cells were cultured in 100-mm plates; then, they were
washed three times with ice-cold PBS and lysed for 10 min on ice with
1 ml ice-cold CSK buffer [10 mm 1,4-piperazinediethanesulfonic acid
(pH 6.8), 100 mm NaCl, 300 mm sucrose, 1 mm MgCl2, 1 mm EGTA, 1
mm dithiothreitol, 1 mm phenylmethylsulfonyl fluoride, and 10 g/ml
aprotinin] containing 0.5% Triton X-100. After low-speed centrifugation
(3000 rpm, 3min at 4C), nucleiwerewashed oncewith 1ml ice-cold 0.5%
Triton X-100 in CSK, centrifuged, and directly resuspended in 1 SDS
sample buffer. Protein amounts of Triton X-100-soluble and -insoluble
fractions deriving from comparable number of cells were loaded on
SDS-PAGE and subjected to Western blotting.
Northern blot
Cells were harvested and stored frozen until RNA was extracted.
Total RNA was isolated by the RNeasy Kit (QIAGEN, Crawley, West
Sussex, UK) and subjected to on-column DNase digestion with the
RNase-free DNase set (QIAGEN) according to the instructions of the
manufacturer. RNA was analyzed by electrophoresis through 1% aga-
rose gel and visualized with ethidium bromide. Total RNA (20 g) was
size fractionated on a denaturing formaldehyde agarose gel and blotted
onto nylon filters (Hybond-N; Amersham Biosciences). The MCM5
probe was a 503-bp RT-PCR product obtained using the following am-
plimers: forward (mcm5f), 5-ACTCAAGCGGCATTACAACC-3; re-
verse (mcm5r), 5-GTCTGGAAGTCCACGCATTT-3.
The MCM7 probe was a 174-bp RT-PCR product obtained using the
following amplimers: forward (mcm7f), 5-TGAACTCGGGAAGAAG-
CA-3; reverse (mcm7r), 5-TGTACGGCATCAGCAAAGAG-3.
We used the random oligonucleotide primer kit (Amersham Bio-
sciences) to label the probe. Hybridizations and washings were per-
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formed under stringent conditions. Autoradiography was performed
with Eastman Kodak (Rochester, NY) XAR films at 70 C for 7 d with
intensifying screens. The image was saved by the Typhoon 8600 laser
scanning system, and the density andwidth of each bandwas quantified
with the ImageQuant 5.0 software.
Reporter gene assay
A 440-bp PCR fragment of the human MCM7 promoter spanning
from500 to60 relative to the transcription start (24) was cloned into
the pGL3 Basic vector (Promega, Madison, WI) carrying the luciferase
reporter gene, to obtain the pGL3-MCM7LUC plasmid. PCR amplifi-
cation was performed on normal human genomic DNA with the fol-
lowing primers: forward, 5- TAGATCTCAGCCCCAAGGGTCTAGG-
3; reverse, 5- TAAGCTTGGGAAGCTGAGAATCTTCCG-3.
The obtained construct was controlled by DNA sequencing. Cells
were transfected by using the LipofectAMINE Reagent (Invitrogen)
according to the instructions of themanufacturer. Cells were transfected
with the different expression plasmids together with 500 ng of the
reporter plasmid DNA and 100 ng pRL-null DNA (a plasmid expressing
the enzyme Renilla luciferase from Renilla reniformis) as an internal con-
trol. In all of the cases, the total amount of transfected plasmid DNAwas
normalized by adding empty vector DNA. After 16 h from transfection,
Firefly and Renilla luciferase activities present in cellular lysates were
assayed using theDual-Luciferase Reporter System (Promega), and light
emission was quantified using the Lumat LB9507 luminometer (EG
Berthold, Bundoora, Australia), as specified by the manufacturer. Each
experiment was performed in triplicate. Expression vectors for wild-
type p53, p53 R248W, and p53 R273H mutant cDNAs, cloned in the
pCMV6 vector, have been described previously (25).
RNA silencing
Premade (Smart Pool) small inhibitory duplex RNAs (siRNA) for
MCM7 were purchased from Dharmacon (Chicago, IL). Another set of
anti-MCM7 siRNA was designed with a program available online
(http://jura.wi.mit.edu/siRNAext/) and synthesized by Proligo (Boul-
der, CO). The sense strand of the second MCM7 siRNA duplex was
5-AAGAUGUCCUGGACGUUUACAdTdT-3. The anti-laminA/C
siRNA (Proligo) used as control was 5-CUGGACUUCCAGAAGAA-
CAdTdT-3. Scrambled control siRNA (Proligo) was 5-ACCGUCGA-
UUUCACCCGGdTdT-3. S11T cells were grown under standard cond-
itions. The day before transfection, cells were plated in six-well dishes
at 50–60% confluency. Transfection was performed with 5 g siRNA
and 6 l oligofectamine reagent (Invitrogen, Groningen, The Nether-
lands), as described previously (26). Cells were harvested at 72 h after
transfection.
Statistical analysis
Significance was determined by the two-tailed Fisher’s test (Statistica
6.0; StatSoft, Tulsa OK). P 0.05 was considered statistically significant.
Results
MCM proteins are highly expressed in ATC
Using immunohistochemistry with specific anti-MCM5
and anti-MCM7 monoclonal antibodies, we evaluated
MCM5 and MCM7 expression levels in 30 normal thyroid
samples, 20 PTC samples, and 52 ATC samples. In 65% of
ATC samples, more than 10% of cells (on average, 25% of the
cells) were positive for MCM5, and, in 73% of the samples,
more than 10% (on average, 30% of the cells) were positive
for MCM7 expression. In both cases, the signal was exclu-
sively nuclear. Virtually no MCM5 and MCM7 expression
(2% of cells) was detected in normal and PTC samples (Fig.
1 and Table 1). Expression of PCNA, a conventional prolif-
eration marker, was also examined. PCNA expression was
significantly correlated (P  0.01) with MCM5 and MCM7
expression being detected mainly in ATC samples (65%).
Only two PTC samples contained a few PCNA-positive cells
(5% of cells) (Table 1). Normal tissue was invariably PCNA
negative. Representative examples of the expression of
MCM5, MCM7, and PCNA are shown in Fig. 1. These find-
ings suggested that MCM5 and MCM7 overexpression may
be related to the high mitotic activity of ATC. We next sep-
arated pure ATC samples from ATC samples containing
well-differentiated (PTC or Hurthle-cell variant FTC) areas
identified by morphological features. The expression of
MCM5 and MCM7 was more prevalent in pure ATC (P 
0.05) and in ATC with coexisting Hurthle-cell areas than in
mixed PTC-ATC samples (Table 2). In parallel, pure ATC
samples were also more frequently PCNA positive than
mixed PTC-ATC samples (P  0.054) (Table 2). More im-
portantly, whenMCM7,MCM5, and PCNAwere detected in
mixed PTC-ATC tumors, their expression was invariably
confined to the ATC area (data not shown).
To verify these data and to analyze other MCM proteins,
we probed protein extracts from 10 thyroid samples with
anti-MCM7, anti-MCM5, anti-MCM2, and anti-MCM6 anti-
bodies. MCM proteins were expressed in ATC samples at
higher levels than in normal and PTC samples (Fig. 2A and
data not shown). Phosphor imaging quantitation showed
that MCM5 and MCM7 were induced, on average, by 4 
FIG. 1. Representative examples of PTC and
ATC samples immunostained with PCNA,
MCM5, and MCM7 antibodies. The primary
antibody was omitted for a negative control
(data not shown).
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1-fold and 8  3-fold, respectively, in ATC with respect to
normal samples.
Transgenic mouse models of thyroid tumors generated
through expression of various oncogenes under the control
of the bovine thyroglobulin gene promoter have become
mainstays of studies of thyroid carcinogenesis (27). RET/
PTC3 (28) and TRK-T1 (29) strains develop carcinomas with
cytological and histological features typical of human PTC
(nuclear grooves, ground-glass nuclei, scant cytoplasm, ab-
sence of mitotic figures, and papillae containing fibrovascu-
lar stalks). Simian virus 40 large T antigen transgenic mice
develop aggressive tumors with a phenotype similar to that
of human ATC (27). We evaluated the expression of MCM
proteins by immunoblot in representative samples of the
three transgenic lines. In parallel, we verified the histologic
diagnosis using hematoxylin and eosin staining. Also in the
murine model, MCM protein expression was higher in ATC
than in PTC or in normal thyroid (Fig. 2B). Finally, we ex-
amined primary cultures derived from two samples each of
normal thyroid, follicular adenoma, PTC, and ATC. As
shown in Fig. 2C, MCM protein expression was higher in
ATC cells than in normal or in differentiated tumor cells.
MCM5 and MCM7 are overexpressed at mRNA level
in ATC
To obtain a semiquantitative estimate of the extent of
MCM5 and MCM7 overexpression, we compared protein
levels in ATC cells (HTU8 and S11T) with those in normal
cells (S11N) by loading increasing amounts of total protein
extracts on SDS-PAGE (Fig. 3A) and compared band inten-
sity by phosphor imaging. MCM5 and MCM7 expression
was about five times greater in ATC cells than in normal cells
(Fig. 3A).
To evaluate whether changes in protein turnover caused
MCM5 andMCM7 up-regulation, wemeasured theMCM5
and MCM7 half-life in ATC and normal cells. Cells were
treated with the protein synthesis inhibitor cycloheximide,
and protein levels were measured at different time points
(Fig. 3B). MCM5 and MCM7 had a half-life of 24 h in both
ATC and normal cells, which indicates that posttransla-
tional mechanisms were not involved in MCM protein
overexpression.
We next measured MCM5 and MCM7 mRNA levels in
TABLE 1. MCM5, MCM7, and PCNA expression in thyroid samples
Tissue MCM5 positivitya MCM7 positivitya PCNA positivitya MCM5/PCNAb MCM7/PCNAb
NT 0% (0/30) 0% (0/30) 0% (0/30)
PTC 0% (0/20) 0% (0/20) 10% (2/20)
ATC 65% (34/52) 73% (38/52) 65% (34/52) 58% (30/52) 61% (32/52)
NT, Normal thyroid.
a Samples were scored positive when more than 10% of cells stained with the antibody.
b Fraction of samples coexpressing PCNA and MCM5 or PCNA and MCM7, respectively.
TABLE 2. MCM5, MCM7, and PCNA expression in ATC
subtypes
ATC subtype (no. of cases)a MCM5positivity
MCM7
positivity
PCNA
positivity
Pure (33) 76% (25/33) 82% (27/33) 73% (24/33)
PTC (14) 43% (6/14) 50% (7/14) 43% (6/14)
Hurthle-cell variant
of FTC (5)
60% (3/5) 80% (4/5) 80% (4/5)
a ATC samples were divided into those showing coexisting WDC
(PTC or Hurthle-cell variant of FTC) foci and those not showing
coexisting differentiated areas (pure).
FIG. 2. Equal amounts (50 g) of protein extracts from normal thy-
roid (NT), PTC, and ATC human tissue specimens (A), from normal
thyroid tissue, PTC (from RET/PTC3 and TRK-T1 transgenic mice),
andATC [from simian virus 40 (SV40) largeT-transgenicmice]mouse
tissue specimens (B), and from primary cultures of human thyroid
cells (C) were immunoblotted with anti-MCM antibodies. The blots
were reprobed with antitubulin (Tub) for normalization. The results
are representative of at least three independent assays.
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normal and ATC cells by Northern blot (Fig. 3C). MCM
mRNA levels were higher in ATC than in normal cells. Im-
portantly, the increase in mRNA (5-fold) was similar to the
increase in protein, which indicates that changes at the
mRNA level caused the enhanced MCM5 and MCM7 ex-
pression. Increased mRNA levels may be due to gene am-
plification, increased transcription, or, less frequently, an
increased mRNA half-life. Amplification of MCM genes has
been described in hypopharyngeal carcinomas (30). Hence,
we determined the MCM2–MCM7 gene copy number by
semiquantitative PCR on genomic DNA in human samples
(tissue samples and primary cell cultures) listed in Fig. 2.
There was no gene amplification in any sample (data not
shown), which suggests that enhanced MCM expression re-
sults from increased transcription.
The humanMCM7gene transcriptional promoter has been
characterized (24). To prove our hypothesis, we cloned the
MCM7 promoter (500 to 60 relative to the transcription
start site) upstream to the luciferase reporter gene (pGL3-
MCM7LUC). The pGL3-MCM7LUC construct (or the empty
vector) was transiently transfected in triplicate in S11N and
ARO cells, and luciferase activity was measured. TheMCM7
promoter displayed a significantly higher (10-fold) activity
in anaplastic cells compared with normal ones (Fig. 3D, top).
MCM7 expression is positively controlled by the E2F (E2
promoter binding factor) transcriptional factor (31), and the
MCM7 promoter contains binding sites for E2F (24). By stim-
ulating increased levels of the CDK inhibitor p21WAF1, p53
is able to reduce pRbphosphorylation levels and, in turn, E2F
transcriptional activity, potentially keeping MCM7 expres-
sion under check (32). Thus, increased MCM7 gene tran-
scription in ATC could be due to the inactivation of p53, a
genetic hallmark of this tumor type (7, 8). We addressed this
possibility by measuring p53 effects on pGL3-MCM7LUC
transcription. As shown in Fig. 3D (bottom), adoptive over-
expression of wild-type p53, but not of two inactive p53
mutants (R248W and R273H), decreased by almost 3-fold
pGL3-MCM7LUC activity in ARO cells.
MCM7 overexpression is required for DNA synthesis in
ATC cells
In mammalian cells, MCM proteins are present in the
nuclei in two forms: one soluble form that can be extracted
by non-ionic detergents and one insoluble form (23). The
insoluble form is the active one, associated with prereplica-
tion chromatin as part of the pre-RC. The soluble form is
considered inactive and no longer capable of binding to
chromatin. We differentially extracted soluble and insoluble
MCM7 from ATC and normal cell nuclei. Although the ratio
chromatin-loaded/chromatin-unloaded MCM7 was slightly
reduced in ATC with respect to normal cells, the absolute
amount of chromatin-boundMCM7was definitely increased
in ATC cells (4-fold by phosphor imaging) (Fig. 4A).
We used two different siRNAs to interfere with MCM7
expression in anaplastic S11T cells. As controls, we used
scrambled silencingRNAand siRNAs for lamin. BothMCM7
siRNAs induced a strong reduction of protein levels at 48 h
after transfection, whereas control oligonucleotides had no
effect (Fig. 4B). Finally, we studied the ability of MCM7-
silenced cells to replicate DNA, by measuring BrdU incor-
poration rate. Decreased MCM7 protein levels reduced the
rate of BrdU incorporation by about 50% in S11T cells, which
suggests that MCM7 expression is required to sustain the
proliferative capacity of ATC cells (Fig. 4B).
Discussion
MCMproteins are required for DNA replication and func-
tion (12). Their expression is restricted to proliferating and
dedifferentiated tissues and is a typical feature of many ma-
lignant and premalignant diseases (16–21). ATC is a very
aggressive tumor that has a high proliferation rate and a
FIG. 3. A, Increasing amounts (10, 20, and 50 g) of protein extracts
from the indicated cell lines were immunoblotted with anti-MCM7,
anti-MCM5, and antitubulin (Tub) antibodies. B, The indicated pri-
mary cell cultures were treated with cycloheximide (CHX) for differ-
ent time points. Lysates (50 g) were run on SDS-PAGE, and MCMs
expression levels were determined by immunoblot. C, MCM mRNA
levels were determined by Northern blot. 28S and 18S RNA levels
were used for normalization. The results are representative of at least
three independent assays. D, Top, The indicated cell lines were tran-
siently transfected with pGL3-MCM7LUC plasmid or the empty vec-
tor; average  SD levels of luciferase activity in three independent
experiments are reported. Bottom, ARO cells were cotransfected with
pGL3-MCM7LUC and the indicated plasmids. Relative luciferase
activity is reported. Average SD results of three independent assays
are reported. wt, Wild type.
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marked genetic instability. Here we show that, in thyroid
tumors, MCM overexpression is present only in ATC. Ac-
cordingly, we propose that MCM protein overexpression is
one of the molecular determinants of this highly mitogenic
phenotype of ATC. Differently, PTC are virtually devoid of
MCM expression. A corollary of these findings is that an
increased mitogenic rate does not play a major role in PTC.
It is also conceivable that MCM overexpression may sustain
the high genetic instability of ATC. In fact, re-replication is
one of the most typical mechanisms of gene copy imbalance
in tumor cells, and it has been demonstrated that MCM
gain-of-function in yeast promotes DNA replication reini-
tiation and gene amplification (33).
Our data indicate that increased gene transcription results
in MCM overexpression in ATC. This fits nicely with the
molecular events described in ATC. Indeed,MCMgene tran-
scription is controlled by the E2F/pRb axis (24, 31), which,
in turn, is controlled by p53. p53 stimulates increased levels
of the CDK inhibitor p21WAF1, thereby inhibiting pRb phos-
phorylation and blocking E2F transcriptional activity (32).
This pathway is probably disrupted in ATC because of their
high prevalence of p53 mutations (7, 8). Accordingly, we
have shown that the p53-null ARO ATC cells display a high
rate of transcription from the MCM7 promoter compared
with normal cells and that reintroduction of a wild-type p53
gene into ARO cells decreases the activity of the promoter.
The mTOR (mammalian target of rapamycin) and MAPK
(mitogen-activated protein kinase) pathways are also known
to stimulate MCM expression (34, 35). Both pathways are
probably hyperactive in ATC due to gain-of-function muta-
tions in Ras (5), BRAF (6), and AKT/PKB (protein kinase B)
(36) and might contribute to MCM up-regulation, as well.
It is the prevailing view that ATC represents a terminal
dedifferentiation of a preexisting PTC or FTC. Comparison
of the histology of fatal PTC with tumors of patients who
survived their disease reveals a high incidence of foci of
spindle and giant cell metaplasia that are indicative of tran-
sition into ATC (2, 3). Although histologic examination of
different samples within the same thyroid tumor is sufficient
for diagnostic identification of ATC, MCM testing could be
used to identify ATC foci in otherwise well-differentiated
carcinomas.
Finally, ATC is refractory to most treatment strategies and
is almost always fatal. Current chemotherapeutic agents do
not induce consistent beneficial therapeutic responses. Local
tumor control with surgery and radiotherapy merely pro-
vides palliation and delays death. MCM proteins promote
DNA synthesis thanks to their helicase function that is es-
sential for DNA replication fork unwinding (14). Our data
raise the possibility of molecular therapy of ATC based on
targeting MCM proteins by interfering with their expression
or blocking their helicase function with small inhibitors.
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Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived
Growth Factor Receptor B Gatekeeper Mutants
Teresa Guida,1Suresh Anaganti,1Livia Provitera,1Richard Gedrich,2 Elizabeth Sullivan,2
Scott M. Wilhelm,2 Massimo Santoro,1and Francesca Carlomagno1
Abstract Purpose:Targeting of KITand platelet-derived growth factor receptor (PDGFR) tyrosine kinases
by imatinib is an effective anticancer strategy. However, mutations of the gatekeeper residue
(T670 in KITand T681in PDGFRh) render the two kinases resistant to imatinib. The aim of this
study was to evaluate whether sorafenib (BAY 43-9006), a multitargeted ATP-competitive
inhibitor of KITand PDGFR, was active against imatinib-resistant KITand PDGFRh kinases.
Experimental Design:We used in vitro kinase assays and immunoblot with phosphospecific
antibodies to determine the activity of sorafenib on KITand PDGFRh kinases.We also exploited
reporter luciferase assays to measure the effects of sorafenib on KITand PDGFRh downstream
signaling events. The activity of sorafenib on interleukin-3^ independent proliferation of Ba/F3
cells expressing oncogenic KITor its imatinib-resistantT670Imutant was also tested.
Results: Sorafenib efficiently inhibited gatekeeper mutants of KITand PDGFRh (IC50 for KIT
T670I, 60 nmol/L; IC50 for PDGFRh T681I,110 nmol/L). Instead, it was less active against activa-
tion loopmutants of the two receptors (IC50 for KITD816V, 3.8 Amol/L; IC50 for PDGFRhD850V,
1.17 Amol/L) that are also imatinib-resistant. Sorafenib blocked receptor autophosphorylation and
signaling of KITand PDGFRh gatekeeper mutants in intact cells as well as activation of AP1-
responsive and cyclin D1gene promoters, respectively. Finally, the compound inhibited KIT-
dependent proliferation of Ba/F3 cells expressing the oncogenic KIT mutant carrying theT670I
mutation.
Conclusions: Sorafenib might be a promising anticancer agent for patients carrying KITand
PDGFRh gatekeeper mutations.
The KIT and platelet-derived growth factor receptors (PDGFR)
are members of the type III subclass of receptor tyrosine
kinases. KIT is the receptor for stem cell factors (SCF), whereas
PDGFRa and PDGFRh are the receptors for platelet-derived
growth factors (PDGF; ref. 1). The structure of these receptors
includes an extracellular domain with five immunoglobulin-
like motifs, a single membrane-spanning domain, and a cyto-
plasmic tyrosine kinase domain. The kinase domain is split by
a kinase insert sequence into an ATP-binding region and a
phosphotransferase region (1).
KIT, PDGFRa, and PDGFRh are frequently activated in
neoplastic diseases. More than 30 gain-of-function mutations
in KIT, either single amino acid changes or small deletions/
insertions, have been identified in such highly malignant
human neoplastic diseases as gastrointestinal stromal tumors
(GIST) and mastocytosis. GISTs are the most common type of
sarcoma arising in the digestive tract and are generally
distinguished from other abdominal sarcomas by the expres-
sion of KIT. Approximately 80% of these tumors show
activating mutations in KIT (2). GIST mutations cluster in
the KIT juxtamembrane region, whereas most mutations
associated with mastocytosis target a specific aspartate residue
(D816) in the kinase activation loop (3). Fusion of PDGFRa
with different genes has been found in chronic myeloid
leukemia and in hypereosinophilic syndrome (4). Moreover,
GIST cases that are negative for KIT mutations almost invariably
display activating point mutations in the juxtamembrane
domain or in the activation loop of PDGFRa (5). The closely
related PDGFRh receptor is often activated by rearrangements
in chronic myelomonocytic leukemia (6).
Imatinib (imatinib mesylate, STI571; Gleevec or Glivec) is an
ATP-competitive inhibitor that has revolutionized drug therapy
of chronic myeloid leukemia. Imatinib is very effective [in vitro
half-maximal inhibitory concentration (IC50) of 25 nmol/L]
against the chronic myeloid leukemia–causing kinase BCR-ABL
(7). It also efficiently inhibits KIT (in vitro IC50, 410 nmol/L)
and PDGFR (in vitro IC50, 380 nmol/L). Consequently, it has
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been successful in the treatment of cancer patients carrying
activating KIT or PDGFR mutations (2, 5, 7). In clinical studies,
75% to 90% of patients with advanced GISTs treated with
imatinib experienced a clinical benefit (7).
However, KIT and PDGFRa variants carrying mutations in
the kinase activation loop (D816 in KIT; refs. 8, 9; and D842
in PDGFRa; ref. 5, which corresponds to D850 in PDGFRh)
are refractory to imatinib. Therefore, mastocytosis (KIT) and
GIST (KIT or PDGFRa) patients with these mutations respond
poorly to imatinib (2, 5). X-ray analysis has shown that
imatinib binds preferentially to the inactive form of the kinase.
It is conceivable that these mutations disrupt the kinase
structure and so disable interaction with the drug (10).
Moreover, some patients who initially respond to imatinib
subsequently relapse. This secondary resistance usually results
from the emergence of tumor clones with mutations in the
kinase domain that prevent drug binding. In particular, some
mutations in KIT (T670I; refs. 11–14) or PDGFR (T674I in
PDGFRa and T681I in PDGFRh) cause imatinib resistance
(15–17). These mutations correspond to the Thr315-to-isoleucine
substitution (T315I) in BCR-ABL that frequently causes
resistance in patients with chronic myeloid leukemia. Given
its role in controlling the susceptibility of kinases to drug
inhibition, this particular residue has been designated as a
‘‘gatekeeper.’’ The gatekeeper threonine interacts with imatinib
via a hydrogen bond. It seems that its replacement with a large
bulky amino acid (isoleucine) prevents the drug-kinase
interaction (10). Other mutations in KIT and PDGFR have
been reported to cause secondary resistance and these include
mutations of D816 in KIT and D842 in PDGFRa (2).
Sorafenib, also known as BAY43-9006, is a multikinase
inhibitor of the bi-aryl-urea chemical class (18). It targets the
RAF family of serine/threonine kinases and the tyrosine kinase
receptors VEGFR-2 (KDR), VEGFR-3 (Flt-4), Flt-3, PDGFR, and
KIT (19). Sorafenib is undergoing advanced clinical trials and
has been recently Food and Drug Administration–approved
under the name of Nexavar for the treatment of advanced renal
cell carcinoma (18). We recently showed that sorafenib is a
potent inhibitor of the wild-type and mutant RET kinase.
Importantly, sorafenib also inhibited RET gatekeeper mutants
(V804M/L; ref. 20). Here, we have investigated the activity of
sorafenib against imatinib-resistant KIT and PDGFRh mutants.
Materials andMethods
Compounds. Sorafenib [BAY 43-9006, N -(3-trifluoromethyl-4-
chlorophenyl)-N ¶-(4-[2-methylcarbamoyl pyridin-4-yl]oxyphenyl)
urea], was provided by Bayer HealthCare Pharmaceuticals. The com-
pound was dissolved in DMSO.
Plasmids. pCMV-KIT, encoding wild-type mouse KIT, and pcDNA
3.1-PDGFRh, encoding wild-type human PDGFRh (21), were kindly
donated by C. Sette (Dept. Sanita’ Pubblica e Biologie Cellulare,
Universita’ di Roma, Rome, Italy) and C.H. Heldin (Ludwig Institute for
Cancer Research, Uppsala University, Uppsala, Sweden), respectively.
PDGFRh T681I and D850V mutants and KIT T670I and KIT D814V
mutants were generated by site-directed mutagenesis. All the mutations
were confirmed by double-strand DNA sequencing. Because the mouse
KIT D814V mutation corresponds to the human KIT D816V, for the
sake of clarity, this mutant is called KIT D816V throughout this article.
Antibodies. Antibodies to KIT and PDGFRh were as follows: KIT (Cell
Signaling Technologies), phospho-KIT (pY721; Biosource, Invitrogen
Corporation), PDGFRh (Santa Cruz Biotechnology) and phospho-
PDGFRh (pY1021; Santa Cruz Biotechnology). Antibodies to SHC were
from Upstate Biotechnology, Inc., antibodies to phospho-SHC (which
recognize phosphorylated SHC at Y317) were from Santa Cruz
Biotechnology, antibodies to mitogen-activated protein kinases (MAPK)
were from Cell Signaling Technologies, and antibodies to phospho-p44/
42 MAPK (pMAPK), specific for MAPK (ERK1/2) phosphorylated at
Thr202/Tyr204, were from Cell Signaling Technologies. Monoclonal anti–
a-tubulin was from Sigma Chemical, Co. Secondary antibodies coupled
to horseradish peroxidase were from Santa Cruz Biotechnology.
Cell cultures and luciferase assays. HEK293 cells were from the
American Type Culture Collection and were grown in DMEM supple-
mented with 10% FCS, 2 mmol/L of L-glutamine, and 100 units/mL of
penicillin-streptomycin (Life Technologies). NIH3T3 fibroblasts were
cultured in DMEM supplemented with 10% calf serum, 2 mmol/L of
L-glutamine, and 100 units/mL of penicillin-streptomycin. HeLa cells
were grown in DMEM supplemented with 10% FCS, 2 mmol/L of
L-glutamine, and 100 units/mL of penicillin-streptomycin.
Transient transfections were carried out with the LipofectAMINE
reagent according to the manufacturer’s instructions (Life Technologies).
HeLa cells (1  106) were transiently transfected with vectors expressing
KIT wt, KIT T670I and KIT D816V, and the AP1-luciferase vector
(Stratagene) containing six AP1-binding sites upstream from the Firefly
luciferase cDNA. Twenty-four hours after transfection, cells were serum-
starved and 100 ng/mL of SCF (Prepotech) was added to the
KIT wt and KIT T670I–transfected cells. NIH3T3 mouse fibroblasts
(1  106) were transiently transfected with vectors expressing PDGFRh
wt, PDGFRh T681I, or PDGFRh D850V, and with the cyclin D1-luciferase
vector (22) containing -1,745 bp of the human cyclin D1 promoter
upstream from the Firefly luciferase cDNA. This vector was kindly
provided by S.J. Gutkind (NIH, Bethesda, MD). Twenty-four hours after
transfection, cells were serum-starved and 100 ng/mL of PDGF BB
(Prepotech) were added to PDGFRh wt and PDGFRh T681I–transfected
cells. Ten nanograms of pRL-null (a plasmid expressing the enzyme
Renilla luciferase from Renilla reniformis) was used as an internal control.
Firefly and Renilla luciferase activities were assayed using the Dual-
Luciferase Reporter System (Promega Corporation). Light emission was
quantitated using a Berthold Technologies luminometer (Centro LB 960)
and expressed as a percentage of residual activity compared with
untreated cells. Average results of three independent assays F SD are
indicated. Student’s t test was used to assess statistical significance.
Stable pools of Ba/F3 cells expressing KIT D557-558 or the imatinib-
resistant D557-558/T670I double mutant were selected for interleukin-3
(IL-3)–independent and G418-resistant growth.3 Cells were main-
tained in RPMI 1640 supplemented with 10% fetal bovine serum
with or without IL-3 culture supplement (BD Biosciences). For cell
proliferation assays, Ba/F3 cells were plated in complete medium with
or without IL-3 and different doses of sorafenib. After 72 h, cell growth
was evaluated by measuring luminescence with a CellTiter-Glo kit
(Promega Corporation). Average IC50 (nmol/L) of the compound for
Ba/F3 cellular proliferation was calculated by using linear regression
methods (GraphPad Software Inc.) from at least three experiments
(minus IL-3: n > 3; plus IL-3: n = 3) and was reported means F SE.
Protein studies. Immunoblotting experiments were done according
to standard procedures. Briefly, cells were harvested in lysis buffer
[50 mmol/L Hepes (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1%
Triton X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF,
10 mmol/L sodium PPi, 1 mmol/L Na3VO4, 10 Ag of aprotinin/mL,
10 Ag of leupeptin/mL] and clarified by centrifugation at 10,000  g .
Protein concentrations were estimated with a modified Bradford assay
(Bio-Rad). Antigens were revealed by an enhanced chemiluminescence
detection kit (Amersham Pharmacia Biotech). Signal intensity was
evaluated with the PhosphorImager (Typhoon 8600, Amersham
Pharmacia Biotech) interfaced with the ImageQuant software.
For the in vitro KIT (23) and PDGFRh (21) kinase assays, proteins
(500 Ag) were immunoprecipitated with the required antibodies.
3 Gedrich R. and Sullivan E., unpublished data.
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Immunocomplexes were recovered with protein A Sepharose beads,
washed five times with kinase buffer, and subjected to in vitro
autophosphorylation by incubating (20 min at room temperature)
the immunocomplex with kinase buffer, 2.5 ACi [g-32P]ATP, unlabeled
ATP (20 Amol/L), and the indicated concentrations of the compound.
Samples were separated by SDS-PAGE; gels were dried and exposed to
autoradiography. Signal intensity was analyzed with the PhosphorIm-
ager (Typhoon 8600) interfaced with the ImageQuant software. The
average results of three experiments done in duplicate FSD are
reported. Kinase activity curves were plotted with the curve-fitting
PRISM software (GraphPad InStat Software).
Statistical analysis. Two-tailed unpaired Student’s t test (normal
distributions and equal variances) were used for statistical analysis.
Differences were significant at P < 0.02. Statistical analyses were done
using the GraphPad InStat Software program (version 3.06.3).
Results
Sorafenib activity on KIT and PDGFRb kinases. The IC50 of
sorafenib for KIT and PDGFRh was 68 and 57 nmol/L,
respectively (19). We tested if sorafenib inhibits imatinib-
resistant KIT and PDGFRh kinases that have mutations in the
gatekeeper residue (KIT T670I and PDGFRh T681I) or in the
activation loop (KIT D816V and PDGFRh D850V; Fig. 1A).
In an immunocomplex kinase assay, we measured KIT T670I
and KIT D816V proteins’ autophosphorylation in vitro in the
presence of different sorafenib concentrations. The drug
strongly inhibited the T670I KIT gatekeeper mutant (IC50,
60 nmol/L), but it was less active on the D816V activation
loop mutant (IC50, 3.8 Amol/L; Fig. 1B). An in vitro kinase assay
with a GST-KIT (TK) recombinant protein carrying the D816V
mutation confirmed these findings (data not shown). Also, the
PDGFRh gatekeeper mutant (T681I) was potently inhibited by
sorafenib in vitro (IC50, 110 nmol/L). Similar to the D816V KIT
mutant, the PDGFRh activation loop mutant (D850V) was less
efficiently inhibited (IC50, 1.17 Amol/L; Fig. 1C).
Next, we tested the inhibitory effects of sorafenib on KIT and
PDGFRh autophosphorylation in intact cells. HEK293 cells
were transiently transfected with either wild-type, gatekeeper, or
activation loop mutant receptors. Transfected cells were treated
with different doses (0.1, 0.5, and 1 Amol/L) of the compound
for 2 h. Because they did not display detectable basal
phosphorylation levels, cells expressing wild-type or gatekeeper
mutant receptors were stimulated with 100 ng/mL of the
specific ligand (SCF for KIT or PDGF BB for PDGFRh) for
10 min before harvesting. Consistent with their oncogenic
properties, activation loop mutants displayed constitutive
kinase activity and did not require ligand stimulation (1).
Receptor activation was monitored by Western blotting with
specific phospho-KIT (pY721) and phospho-PDGFRh
(pY1021) antibodies. Relative phosphorylation levels in com-
pound-treated compared with vehicle-treated cells were calcu-
lated with PhosphorImager. Sorafenib was very effective in
blocking wild-type KIT and PDFGRh phosphorylation (Fig. 2).
At the 100 nmol/L dose, the compound blocked receptor
phosphorylation by >90%. Moreover, gatekeeper mutants were
very sensitive to sorafenib (100 nmol/L sorafenib blocked KIT
T670I and PDGFRh T681I receptor phosphorylation in intact
cells by 80%; Fig. 2). Instead, the drug was clearly less active
against the activation loop mutants: 1 Amol/L of sorafenib
inhibited KIT D816V and PDGFRh D850V by f70%, whereas
the inhibitory effect at 100 nmol/L was barely detectable.
Fig. 1. Effect of sorafenib on the in vitro
kinase activity of KITand PDGFRh
gatekeeper and activation loop mutants.
A, the KITand PDGFRhmutants studied.
Black bars, the transmembrane domain.
B, HEK293 cells were transiently transfected
with CMV-6 vectors expressing KIT T670I
and KIT D816V mutants. KIT proteins were
immunoprecipitated (500 Ag) and
subjected to in vitro autophosphorylation.
Signal intensity was analyzed with
PhosphorImager.The average results of
three experiments done in duplicateF SD
are plotted with the curve-fitting PRISM
software.The IC50 for each protein is
indicated. C, HEK293 cells were transiently
transfected with pcDNA 3.1vectors
encoding PDGFRh T681I and D850V
mutants. Proteins were immunoprecipitated
(500 Ag) and subjected to in vitro
autophosphorylation assay. Reactions
were processed as described above.
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Sorafenib activity on KIT and PDGFRb signaling. Then, we
investigated whether sorafenib intercepts KIT and PDGFRh
downstream signaling. Ligand-stimulation of HEK293 cells
adoptively expressing wild-type KIT and PDGFRh or their
gatekeeper mutant–induced SHC adaptor protein and MAPK
phosphorylation (ref. 24; Fig. 3). The activation loop mutants
of KIT and PDGFRh also induced SHC and MAPK phosphor-
ylation and did not require ligand triggering because of their
constitutive kinase activity (Fig. 3). Treatment of cells with
different doses of sorafenib strongly inhibited wild-type and
gatekeeper mutant–dependent SHC and MAPK phosphoryla-
tion. In contrast, stimulation of SHC and MAPK phosphory-
lation by the activation loop mutants was less efficiently
blocked by sorafenib; in this case, marked inhibition was seen
only at a concentration of 1 Amol/L (Fig. 3).
The effects of sorafenib on KIT and PDGFRb transcriptional
activity. In a first set of experiments, we noted that KIT
activation triggered the transcription of a luciferase reporter
downstream from an AP1-responsive promoter in NIH3T3
murine fibroblasts and that PDFGRh was a potent activator of
a cyclin D1 promoter in HeLa cells. For PDFGRh, we could
not use NIH3T3 cells because fibroblasts express endogenously
high levels of the receptor (data not shown). Thus, we
evaluated whether sorafenib blocked receptor activity on these
promoters. The AP1-luciferase reporter activity was hindered
when KIT and KIT T670I cells were treated for 24 h with
0.1, 0.5, and 1 Amol/L of sorafenib (f10-fold reduction at
1 Amol/L; P < 0.02; Fig. 3C). Similarly, cyclin D1-luciferase
promoter activity was inhibited when PDGFRh and PDGFRh
T681I cells were treated with 0.1, 0.5, and 1 Amol/L of
sorafenib (f40-fold reduction at 1 Amol/L; P < 0.02; Fig. 3D).
Although sorafenib was less active on the activation loop
mutants of the two receptors, it still exerted a significant
inhibitory activity at 1 Amol/L (f2-fold reduction of KIT
D816V and f7-fold reduction of PDGFRh D850V) and some
activity at 0.5 Amol/L (1.5-fold reduction for KIT D816V and
4-fold reduction for PDGFRh D850V; P < 0.02; Fig. 3C and D).
The effects of sorafenib on KIT mitogenic activity. The murine
pro–B cell line Ba/F3 requires the cytokine IL-3 for prolifera-
tion and survival. Expression of constitutively active KIT
mutants confers IL-3–independent growth to Ba/F3 cells (25).
Thus, Ba/F3 cells were transfected with plasmids expressing
either the imatinib-sensitive oncogenic KIT mutant containing
a deletion of residues 557 to 558 (D557-558) in the juxta-
membrane domain or the imatinib-insensitive KIT double
mutant containing both the D557-558 and the T670I mutations
(3). In the absence of IL-3, sorafenib potently inhibited the
growth of both the D557-558 and D557-558/T670I KIT–
expressing cells (Table 1). The compound had virtually no
effect on the proliferation of parental or Ba/F3-transfected cells
grown in the presence of IL-3, indicating that the antiprolifer-
ative effects of the compound were selective and dependent on
activated KIT signaling (Table 1).
Discussion
Here we show that sorafenib targets a number of mutant KIT
and PDGFRh kinases. Thus, based on its advanced clinical
Fig. 2. Effect of sorafenib on KITand
PDGFRh gatekeeper and activation loop
mutants in intact cells. HEK293 cells were
transfected with vectors expressing KIT,
KIT T670I, KIT D816V (A), or PDGFRh,
PDGFRh T681I, and PDGFRhD850V (B).
Twenty-four hours after transfection, cells
were serum-starved.Twohours before being
harvested, cells were treated with the
indicated concentration of sorafenib. KITwt
and KIT T670I ^ transfected cells were
stimulated with100 ng/mL of SCF for
10 min, whereas PDGFRh wt and PDGFRh
T681I ^ transfected cells were stimulated
with100 ng/mL of PDGFBB for10 min.
Cell lysates were analyzed by immunoblot
with the antibodies to KIT, phospho-KIT
(pYKIT), PDGFRh (PDGFRb) and
phospho-PDGFRh (pYPDGFRb). A,
proteins (0.5 mg) were immunoprecipitated
with anti-KIT before being subjected to
immunoblot (top andmiddle). Each
experiment is representative of at least three
independent experiments. Signal intensity
was analyzed with PhosphorImager.
Relative phosphorylation levels compared
with vehicle-treated cells were calculated.
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development, sorafenib may be effective in the treatment of
cancer driven by KIT or PDGFR mutations. We also show that
sorafenib is less active against the activation loop mutants of
KIT and PDGFRh (D816V in KIT and D850V in PDGFRh) than
against wild-type and gatekeeper mutants (T670 in KIT and
T681 in PDGFRh) of the two receptors. Nevertheless, in intact
cells, we observed the inhibition of activation loop mutants at
concentrations between 0.5 and 1.0 Amol/L. Whatever the
mechanism, such an increase in potency in cellular assays with
respect to in vitro kinase activity warrants further investigation
to verify whether sorafenib could also be used to inhibit these
mutants in a clinical setting.
Noteworthy, other compounds proved their efficacy against
KIT or PDGFR activation loop mutants. These included
dasatinib (BMS-354825), a small molecule inhibitor of SRC
and ABL tyrosine kinases (26); PKC412, a staurosporine-
derived tyrosine kinase inhibitor that targets protein kinase C;
VEGFR-2, FLT-3, PDGFR and KIT (15, 27), and EXEL-0862,
Fig. 3. Effect of sorafenib on KITand PDGFRh intracellular signaling. HEK293 cells were transfectedwith vectors expressing KITwt, KIT T670I, KIT D816V (A), PDGFRhwt,
PDGFRh T681I, and PDGFRhD850V (B).Twenty-four hours after transfection, cells were serum-starved.Two hours before being harvested, cells were treated with the
indicated concentration of sorafenib, and KITwt and KIT T670I ^ transfected cells were then stimulatedwith100 ng/mL of SCF for10 min, whereas PDGFRhwt and PDGFRh
T681I ^ transfected cells were stimulated with100 ng/mL of PDGFBB for10 min. Cell lysates were analyzed by immunoblot with antibodies to SHC, phospho-SHC (pSHC),
MAPK, and phospho-p44/42 MAPK (pMAPK). Each experiment is representative of at least three experiments. C, NIH3T3 cells (1 106) were transiently transfected with
vectors expressing KITwt, KIT T670I, and KITD816V, and theAP1-luciferase vector.Twenty-four hours after transfection, cells were serum-starved and100 ng/mLof SCFwas
added to the KITwt and KIT T670I ^ transfected cells.D, HeLa cells (1 106) were transiently transfected with vectors expressing PDGFRh wt, and PDGFRh T681I- and
PDGFRhD850V, andwith the cyclin D1-luciferase vector.Twenty-four hours after transfection, cells were serum-starved and100 ng/mL of PDGFBBwere added to PDGFRh
wt and PDGFRh T681I ^ transfected cells.The drug was added 24 h before harvesting at the indicated concentrations. Luciferase activity is expressed as a percentage of
residual activity comparedwith cells that hadnot been treatedwith sorafenib. Columns, average results of three independent assays; bars, SD; *, P < 0.02, Student’s t test was
used to assess statistical significance (vehicle versus treatment).
Table 1. Sorafenib inhibits growth of Ba/F3 cell expressing the imatinib-resistant D557-558/T670I KIT
gatekeeper double mutant
Compound Ba/F3 cells*
#557-558 #557-558/T670I Parental
-IL-3 +IL-3 -IL-3 +IL-3 +IL-3
Sorafenib (IC50) 6 F 1 4,920 F 1,070 14 F 2 5,940 F 1,920 6,400 F 1,360
*Parental Ba/F3 cells or cells expressing KIT D557-558 or the imatinib-resistant D557-558/T670I double mutant were plated in complete
medium with or without IL-3 and different doses of sorafenib. After 72 h, cell growth was evaluated by measuring luminescence with a CellTiter-
Glo kit. Average IC50 (nmol/L) for Ba/F3 cellular proliferation was calculated by using linear regression method (GraphPad Software, Inc.) from
at least three experiments (minus IL-3: n > 3; plus IL-3: n = 3) and is reported as means F SE.
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a novel kinase inhibitor active against fibroblast growth factor
receptors, VEGFRs, PDGFR, FLT3, and KIT (Table 2; ref. 28).
On the other hand, gatekeeper mutation induces resistance to
many inhibitors, rendering the identification of second-line
treatments quite difficult (29–31). Although other strategies
have been envisaged to counteract the activity of these mutants,
such as the use of the heat shock protein 90 inhibitor 17-
allylamino-18-demethoxy-geldanamycin (32), compounds
able to inhibit gatekeeper mutants are urgently needed to
provide a solution to the challenge of molecular resistance due
to secondary mutations at this site. Thus far, only a few
compounds have been reported to be active on these mutants.
SU-11248 was found to inhibit the KIT T670I kinase (33, 34)
and PKC412 inhibited both KIT and PDGFR gatekeeper
mutants (Table 2; refs. 15, 35). Our data indicate that sorafenib
is active against KIT and PDGFR gatekeeper mutations. Indeed,
these mutants were efficiently inhibited at a drug concentration
(60 nmol/L for KIT T670I and 110 nmol/L for PDGFRh T681I)
that is well below the average plasma concentration of the
drug. Pharmacokinetic studies have shown that on multiple
oral doses of 400 mg b.i.d., the Cmax value of sorafenib was
9.35 mg/L, which corresponds to a concentration off20 Amol/L.
Up to 99% of the drug is bound to serum proteins leading to
an unbound concentration of the drug of f200 nmol/L (36).
Consistent with our findings, Lierman and coworkers have
recently shown that FIPL1-PDGFRa, the oncogenic rearrange-
ment of PDGFRa, another PDGFR family member, found in
HES (patients with idiopathic hypereosinophilic syndrome),
and its T674I gatekeeper mutant are efficiently inhibited by
sorafenib (37).
In conclusion, our study suggests that sorafenib might be a
useful therapeutic agent to treat tumors harboring the imatinib-
resistant KIT T670I or PDGFR T681I mutants. In the chronic
myeloid leukemia model, it has been reported that the
combination of imatinib with an inhibitor of imatinib-resistant
BCR-ABL mutants can be used to prevent the emergence of
resistance (38). Similarly, the combination of sorafenib with
imatinib might be envisaged to reduce the risk of the emergence
of treatment-resistant neoplastic clones harboring KIT or
PDGFR mutants.
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Table 2. Inhibitory concentration of various TKIs against KIT and PDGFR imatinib-resistant mutants
Mutants Receptor Sorafenib
(nmol/L)
Dasatinib
(nmol/L)
PKC412
(nmol/L)
EXEL-0862
(nmol/L)
SU-11248
(nmol/L)
Gatekeeper KIT 60 10,000 (26) 100 (35) Not reported 70 (33)
PDGFR 110 Not reported 50 (15) Not reported Not reported
Activation loop KIT 3,800 1-100 (26) 44 (27) 42 (28) Not reported
PDGFR 1,170 Not reported 50 (39) Not reported >1,000 (34)
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RET Y806C mutation causes resistance to ZD6474 
Identification of tyrosine 806 as a molecular determinant of RET kinase 
sensitivity to ZD6474 
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ZD6474 (vandetanib, Zactima™) is an anilinoquinazoline used to target the receptor tyrosine 
kinase RET in familial and sporadic thyroid carcinoma (IC50: 100 nM). The aim of this study 
was to identify molecular determinants of RET sensitivity to ZD6474. Here, we show that 
mutation of RET tyrosine 806 to cysteine (Y806C) induced RET kinase resistance to ZD6474 
(IC50: 933 nM). Y806 maps close to the gate-keeper position at the  RET kinase nucleotide-
binding pocket. Although tyrosine 806 is a RET auto-phosphorylation site, its substitution to 
phenylalanine (Y806F) did not markedly affect RET susceptibility to ZD6474 (IC50: 87 nM), 
suggesting that phosphorylation of Y806 is not required for compound binding. Accordingly, 
the introduction of a phosphomimetic residue (Y806E) also caused resistance to ZD6474, 
albeit of a lesser degree (IC50: 512 nM) than the cysteine mutation. Y806C/E RET mutants 
were also resistant to ZD6474 with respect to intracellular signalling and activation of an 
AP1-responsive promoter. We conclude that Y806 is a molecular determinant of RET 
sensitivity to ZD6474. Y806C is a natural RET mutation identified in a patient affected by 
multiple endocrine neoplasia type 2B. Based on its rare occurrence, it is unlikely that Y806C 
will be a frequent cause of refractoriness to ZD6474; however, it may be envisaged that 
mutations at this site can mediate secondary resistance formation in patients treated with the 
compound. 
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Small molecule tyrosine kinase inhibitors (TKI) are effective in a variety of human cancers 
driven by activation of specific tyrosine kinases (Krause & Van Etten 2005; Baselga 2006). A 
paradigmatic example is imatinib mesylate (Gleevec®, STI571), an ATP-competitive 
inhibitor of BCR-ABL, KIT and PDGFR kinases. Imatinib is used for the treatment of 
chronic myeloid leukaemia (CML) patients harbouring the BCR-ABL translocation and of 
gastrointestinal stromal tumours (GIST) patients harbouring KIT or PDGFRα mutations 
(Sherbenou & Druker 2007).  
 
Although most CML cases initially respond to imatinib, relapses are frequent, particularly in 
patients with advanced disease. Point mutations within the kinase domain of BCR-ABL are 
the most frequent causes of resistance. Such mutations can either remove residues that are 
critical for drug-kinase interaction, or create steric hindrance or display an allosteric effect, 
preventing the kinase from adopting the correct conformation for drug binding (Daub et al. 
2004; Nardi et al. 2004; Weisberg et al. 2007). The best described resistance-associated 
mutation affects T315, the so called “gate-keeper” site. T315 is located at the base of the 
ATP-binding pocket, where also the drug binds. Amino acid changes at the gate-keeper site 
are able to confer resistance not only to imatinib but also to other BCR-ABL inhibitors, such 
as dasatinib and nilotinib (Kantarjian et al. 2006; Talpaz et al. 2006). Moreover, mutation of 
the corresponding residue has been linked to resistance of other tyrosine kinases to their 
specific TKI (Pao et al. 2005). 
 
How resistance to kinase inhibitors develops in patients is being understood. The short lag of 
time in which resistance develops in CML patients has suggested that resistance-causing 
mutations are present before treatment in a few tumour cells, in cis with the oncogenic 
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alteration, and are maintained in the tumour cell population because they increase the relative 
fitness of the mutated cell clones. Tumour cells harbouring the resistance-causing mutation, in 
turn, could be positively selected upon treatment with imatinib (secondary resistance) 
(Sherbenou & Druker 2007). In other cases, the initial oncogenic mutation per se is refractory 
to the drug (primary resistance). For instance, tumor-associated KIT and PDGFRα variants 
displaying gain-of-function mutations in the kinase activation loop (D816 in KIT and D842 in 
PDGFRα) are refractory to imatinib, and patients harbouring these mutations respond poorly 
to imatinib (Corless et al. 2005). Similarly, a germline EGFR mutation (T790M) found in rare 
families predisposed to lung cancer not only activates the oncogenic potential of EGFR but 
also causes resistance to the EGFR TKIs gefitinib and erlotinib (Bell et al. 2005). An 
understanding of the molecular basis of drug sensitivity and resistance is required to interpret 
results of clinical trials with TKIs, to select patients for treatment and to design strategies 
aimed at circumventing resistance formation (Kantarjian et al. 2006; Talpaz et al. 2006; 
O’Hare et al. 2006; Shah et al. 2007). 
 
RET receptor tyrosine kinase is frequently activated in thyroid tumours (Santoro & 
Carlomagno 2005). Germline point mutations affecting the extracellular or kinase domains of 
RET are associated to the autosomal dominant multiple endocrine neoplasia type 2 (MEN 2) 
syndromes (MEN 2A, MEN 2B, familial medullary thyroid cancer), characterized by the 
occurrence of medullary thyroid carcinoma (MTC), pheochromocytoma, parathyroid 
adenoma, and ganglioneuromatosis of the gut. Somatic RET point mutations are found in 30-
40% of sporadic MTC cases (Marx 2005; Schlumberger et al. 2008). Most of the MEN 
2/MTC-associated RET mutations either target extracellular cysteine residues (typically in 
MEN 2A), or the methionine 918 (typically in MEN 2B) or few other residues (E768, L790, 
Y791, V804, S891) in the RET kinase domain. Some patients harbour more rare mutations in 
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other codons or small insertions/deletions (Santoro & Carlomagno 2005). Moreover, 
chromosomal rearrangements involving the RET kinase encoding domain (chimeric 
RET/PTC oncogenes) are found in papillary thyroid carcinoma (PTC) (Santoro & 
Carlomagno 2005). Both MEN 2/MTC-associated point mutations and RET/PTC 
rearrangements switch on the enzymatic function of RET in a ligand-independent manner 
(Santoro & Carlomagno 2005). Whereas adjuvant radiometabolic therapy with 
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131I is effective 
after surgery for PTC, MTC does not respond to conventional radiotherapy or chemotherapy, 
and early surgery remains the only treatment for this tumour (Schlumberger et al. 2008).  
 
ZD6474 (Zactima, vandetanib) is an orally bioavailable anilinoquinazoline with strong 
inhibiting activity against VEGFR-2 (IC50 = 40 nM) and EGFR (IC50 =500 nM) kinase 
function (Ryan & Wedge 2005). ZD6474 is also a potent inhibitor of the RET kinase (IC50 = 
100 nM) (Carlomagno et al. 2002). The compound could arrest the growth of human thyroid 
cancer cell lines spontaneously harbouring RET oncogenes and was effective against a 
Drosophila model of PTC and MTC (Vidal et al. 2005). The X-ray structure of ZD6474-
RET(TK) complex shows that the compound docks into the ATP-binding pocket of the RET 
kinase (Knowles et al. 2006). In a phase II trial of hereditary MTC patients who had a 
germline RET mutation, ZD6474 treatment was associated with objective tumour responses, 
with evidence of prolonged disease stabilization and clinical benefit in up to half the patients 
(Wells et al. 2006). Multicentric placebo-controlled phase II trials are in progress with this 
drug in thyroid cancer patients (Schlumberger et al. 2008). 
 
Pre-clinical in vitro studies have demonstrated that ZD6474 inhibited the wild-type enzyme 
and several activated mutant forms of RET, with the notable exception of RET proteins 
carrying mutations in residue V804 (V804L and V804M). In fact, the IC50 for RET kinase 
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inhibition increased by about 50-fold in the presence of V804L and V804M mutations 
(Carlomagno et al. 2004). V804 in RET corresponds to the “gate-keeper” (T315) residue in 
ABL. V804 mutations are present alone or in conjunction with other RET mutations in MEN 
2 carriers (∼4% of cases) and in sporadic MTC and could therefore cause resistance to 
ZD6474.  
 
Here, we screened natural RET oncogenic proteins, corresponding to BCR-ABL imatinib 
resistant mutants, for ZD6474 response in vitro and in intact cells. 
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Compound 
ZD6474 (Zactima™, vandetanib) (AstraZeneca Pharmaceuticals, Macclesfield, UK) was 
dissolved in dimethyl sulfoxide (DMSO) at a concentration of 50 mM and stored at -80° C. 
1000X stock solution was freshly generated for each single experiment and the equivalent 
amount of vehicle (DMSO) was used as control.  
 
Cell culture and plasmids 
HEK 293 and HeLa cells were from American Type Culture Collection (ATCC, Manassas, 
VA) and were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% fetal calf serum, 2 mM L-glutamine, and 100 units/ml penicillin-streptomycin (GIBCO, 
Paisley, PA). Transient transfections were carried out with the lipofectamine reagent 
according to manufacturer's instructions (GIBCO). The alignment between RET and ABL 
kinase domains was made with the “Lalign” tool available at the ExPASy proteomic tools 
web site (www.expasy.ch). RET mutations V804M, E805K, Y806C, Y806E, Y806F, Y806S, 
Y806G, E884K and D898V were generated by site-directed mutagenesis and inserted in the 
background of an oncogenic RET C634R allele in the pcDNA 3.1 vector (Carlomagno et al. 
2004). The presence of mutation was confirmed by double-strand DNA sequencing. 
 
Protein studies 
Protein lysates were prepared according to standard procedures. Briefly, cells were lysed in a 
buffer containing 50 mM HEPES, pH 7.5, 1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM 
EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM 
phenylmethylsulphonyl fluoride (PMSF) and 1 μg/mL aprotinin. Lysates were clarified by 
centrifugation at 10,000 X g for 15 min. Lysates containing comparable amounts of proteins, 
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as estimated by a modified Bradford assay (Bio-Rad, Munich, Germany) were subjected to 
direct Western blot. Immune complexes were detected with the enhanced chemiluminescence 
kit (Amersham Pharmacia Biotech, Little Chalfort, UK). Signal intensity was analyzed using 
a Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) interfaced with the 
ImageQuant software. Polyclonal anti-phospho-Shc, that recognizes phosphorylated Shc at 
Y317, was from Upstate Biotechnology Inc. (Lake Placid, NY). Polyclonal anti-Shc was from 
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to MAPK were from Cell Signaling 
Technologies (Beverly, MA, USA), and antibodies to phospho p44/42-MAPK (pMAPK), 
specific for MAPK (ERK1/2) phosphorylated at Thr202/Tyr204, were from Cell Signaling 
Technologies. Anti-RET is a polyclonal antibody raised against the tyrosine kinase protein 
fragment of human RET (Santoro et al.1994). Anti-phospho905 and anti-phospho1062 are 
phospho-specific polyclonal antibodies recognizing RET proteins phosphorylated at the 
corresponding sites (Salvatore et al. 2000; Carlomagno et al. 2003). Blots were incubated 
with primary antibodies for 1 hour at room temperature, washed and incubated with the 
appropriate secondary antibodies (goat anti-rabbit 1:5,000) coupled to horseradish peroxidase 
(Santa Cruz Biotechnology). Signal intensity was evaluated with the Molecular Imager Gel 
Doc System (Biorad) interfaced with the Quantity One software. Curves of ZD6474 inhibition 
were plotted to identify IC50 dose for each RET mutant in vivo autophosphorylation. 
 
In vitro kinase assay 
RET proteins were immunoprecipitated from HEK 293 cells transfected with different 
mutants. Immunocomplexes were subjected to an in vitro kinase assay by incubation (20 min 
at room temperature) in kinase buffer containing 200 μM poly-(L-glutamic acid-L-tyrosine 
[poly-GT]) (Sigma Chemical Co), 2.5 μCi [γ-32P] ATP and unlabelled ATP (20 μM) and the 
indicated concentrations of the compound (Carlomagno et al. 2002). Samples were spotted on 
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Whatman 3MM paper (Springfield Mill, UK) and 32P incorporation was measured with a β-
counter scintillator (Beckman Coulter, Unterschleissheim-Lohhof, Germany).  
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Luciferase activity assay 
1x106 HeLa cells were transiently co-transfected with RET mutants and the AP1-Luc vector 
(Stratagene, Garden Grove, CA) containing six AP1 binding sites upstream from the Firefly 
luciferase cDNA. Twenty-four hours after transfection, cells were serum-starved and the 
indicated concentration of ZD6474 or vehicle was added. Cells were harvested 48 h after 
transfection. Ten ng of pRL-null (a plasmid expressing the enzyme Renilla luciferase from 
Renilla reniformis) served as an internal control. Firefly and Renilla luciferase activities were 
assayed using the Dual-Luciferase reporter system (Promega Corporation, Madison, WI) and 
expressed as percentage of residual activity compared to cells treated with vehicle.  
 
Assessment of the structural impact of various Y806 mutations. 
The structure of the RET kinase domain in complex with ZD6474 (PDB: 2ivu) (Knowles et al 
2006) was examined using the PyMOL Molecular Graphics System (http://www.pymol.org). 
Tyrosine 806 was replaced with the different mutations and the structural consequences were 
assessed. 
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Statistical analysis 
Kinase activity curves were plotted using the curve-fitting PRIZM software (GraphPad 
Software). The ANOVA Post-Hoc Tukey-Kramer multiple comparison test was used to 
assess statistical significance of luciferase assay. InStat3 GraphPad Software was used. 
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Identification of Y806 as a molecular determinant of RET sensitivity to ZD6474 
inhibition 
We aligned the RET and ABL kinase domains and found that several RET residues, naturally 
mutated in some MEN 2/MTC patients, correspond to positions in ABL whose mutation 
causes imatinib resistance (Fig. 1A). RET changes in E768, L790 and A883 residues 
(corresponding to E279, L301 and R372 in ABL, respectively) do not affect RET kinase 
sensitivity to ZD6474, as previously reported (Carlomagno et al. 2004). Here, we evaluated 
the effect of E805K, Y806C, E884K and D898V (corresponding to the imatinib-resistant 
E316D, ABL F317L, E373K and L387M mutants, respectively) on RET kinase sensitivity to 
ZD6474 (Fig. 1A). The E805K mutation was found in tandem with V804M in a patient with a 
MEN 2B phenotype (Cranston et al. 2006). The adjacent Y806 residue was found mutated to 
cysteine (Y806C) at the germline level in combination with mutation V804 in a patient with 
MEN 2B-like clinical presentation (Miyauchi et al. 1999; Iwashita et al. 2000). Notably, 
phospho-aminoacid  analysis included Y806 among RET kinase autophosphorylation sites 
(Kawamoto et al. 2004). Both E805 and Y806 map in the RET catalytic domain to the same 
loop containing the gate-keeper V804 residue (Knowles et al. 2006). Moreover, the E884K 
mutation was identified in individual sporadic MTC case (Uchino et al. 1999). Finally, 
residue D898 has been found deleted in a sporadic MTC patient. The same aspartic acid in 
KIT kinase was shown to mediate resistance to imatinib when mutated to valine and ABL 
L387 residue, located in the corresponding position, was mutated in an imatinib-resistant 
kinase (Oriola et al. 2002).   
 
Because these mutations weakly activate RET kinase (Miyauchi et al. 1999; Iwashita et al. 
2000), we introduced them in the background of a constitutively active RET allele carrying 
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the MEN 2A-associated extracellular C634R mutation. C634R strongly activates RET by 
inducing a constitutive dimerization of the receptor through the formation of extracellular 
disulfide bonds without affecting the natural conformation of RET kinase domain (Santoro & 
Carlomagno 2006). Intact cells expressing RET mutants were treated with different ZD6474 
doses and RET activity was measured by immunoblotting with anti-phospho RET antibodies 
that recognise the Y905 and Y1062 autophosphorylation sites (Salvatore et al. 2000; 
Carlomagno et al. 2003). When phosphorylated, Y1062 functions as multi-docking site for 
intracellular signalling proteins, whereas Y905 resides in the activation loop and its 
phosphorylation is necessary to maintain the kinase in an active conformation (Iwashita et al. 
2000; Hayashi et al. 2000). As shown in Fig. 1B, ZD6474 inhibited RET proteins carrying 
C634R/E805K (IC50 = 100 nM), C634R/E884K (IC50 = 200 nM) or C634R/D898V (IC50 = 
200 nM) tandem substitutions similarly to RET C634R protein (IC50 = 100 nM). In contrast, 
the RET C634R/Y806C protein was highly resistant to the drug (IC50 > 1000 nM). The 
ZD6474-resistant RET C634R/V804M mutant served as control (IC50 > 1000 nM). (Fig. 1B).  
 
Structure-function analysis of the effect of RET Y806 mutation 
We generated RET mutants carrying mutations of Y806 to different amino acids, namely 
glycine (Y806G), serine (Y806S), glutamic acid (Y806E) and phenylalanine (Y806F), in the 
background of RET C634R. Mutations Y806G and Y806S knocked-down kinase activity (not 
shown) and were not studied further. The substitution of tyrosine 806 with the non-
phosphorylatable phenylalanine (Y806F) did not significantly affect kinase activity. In 
addition, it did not modify RET sensitivity to ZD6474, which suggested that Y806 
phosphorylation was not necessary for ZD6474 binding (Fig. 2A). In contrast, the substitution 
of tyrosine 806 with the phospho-mimetic glutamate (Y806E) greatly reduced RET sensitivity 
to ZD6474, and thus had an effect comparable to the Y806C change (Fig. 2A).  
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Subsequently, we carried out an in vitro kinase assay and measured ZD6474 in vitro IC50 for 
the various RET Y806 mutants. As shown in Fig. 2B, ZD6474 IC50 for the RET 
C634R/Y806F protein was similar to RET C634R (87 nM vs 100 nM), whereas the IC50 
values for RET C634R/Y806E and RET C634R/Y806C were increased by 5-fold (512 nM) 
and 10-fold (933 nM), respectively.  
 
Analysis of ZD6474 activity on intracellular signalling of RET Y806 mutants 
RET phosphorylation on Y1062 results in a docking site for Shc and other adaptor proteins 
that, in turn, serve as anchors for Grb2/Sos and Grb2/Gab complexes thereby mediating 
downstream RET signals (Hayashi et al. 2000). In turn, Grb2 containing complexes activate 
the PI3K/AKT and RAS/MAPK pathways. ZD6474 strongly knocked-down RET C634R-
induced Shc and MAPK activation measured as phosphorylation of the two proteins. Once 
again, RET C634R/Y806C and RET C634R/Y806E, as RET C634R/V804M, showed 
resistance to ZD6474 inhibition (Fig. 3A).  
 
Finally, we tested whether ZD6474 obstructed RET-mediated activation of an AP1-
responsive promoter fused to the luciferase reporter. As shown in Fig. 3B, the compound 
reduced RET C634R activity to less than 50% at 250 nM and completely abolished promoter 
activation at 1 μM. Instead, ZD6474, even at a concentration of 5 μM, had virtually no effect 
on RET C634R/V804M-mediated luciferase stimulation. Compared with RET C634R, RET 
mutants C634R/Y806C and RET C634R/Y806E were also relatively resistant to the effects of 
ZD6474, although to a lesser extent than RET C634R/V804M.  
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The efficacy of ZD6474 in targeting RET oncogenic mutations in medullary thyroid 
carcinoma is now being evaluated in phase II clinical trials. Although clinical benefit from 
ZD6474 is likely to derive from inhibition of both VEGFR-2 and EGFR kinase activities in 
addition to RET kinase, it will be necessary to identify RET mutations that respond best to the 
compound in order to interpret the results of these trials and subsequently to select the most 
suitable candidates for ZD6474 treatment. Here we screened natural oncogenic RET kinase 
mutants for ZD6474 response. The majority of these mutants, although homologous to ABL 
mutants resistant to imatinib, retains ZD6474 responsiveness. An important exception is 
Y806C that, similar to V804M/L (Carlomagno et al. 2004), impairs ZD6474 efficacy.  
 
Based on the recently resolved RET kinase X-ray structure (Knowles et al. 2006), tyrosine 
806 is located between the kinase N- and C-lobes in the hinge region that forms part of the 
nucleotide binding pocket (Fig. 4A). The Y806 side chain stacks against the aliphatic part of 
the lysine 740 (K740) side chain and the main chain of the adjacent alanine 807 (A807) (Fig. 
4B). The position equivalent to Y806 in other kinases is usually hydrophobic and aromatic, 
which might explain why we found that substitution of this residue with glycine or serine 
dramatically affects kinase function. Y806 is in direct Van der Waals contact with ATP and 
with ZD6474. Conservative substitution of Y806 to phenylalanine (Y806F) preserves the 
shape and hydrophobicity of this part of the nucleotide pocket. Therefore this mutated RET is 
likely to maintain contacts with ZD6474 using Y806, which explains why the Y806F 
mutation does not affect the sensitivity of RET towards ZD6474. On the other hand, the 
effects of the Y806C and Y806E substitutions are subtle and unpredictable compared to the 
V804M/L mutation, which causes a clear steric hindrance (Knowles et al. 2006). 
Replacement of Y806 by a smaller cysteine will leave a cavity thereby leading to minor 
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structural alterations to the nucleotide-binding pocket, so that the kinase retains the ability to 
bind and hydrolyse ATP. On the other hand, these changes could affect affinity for ZD6474 
by losing direct Van der Vaals interactions. Substitution of Y806 with the acidic glutamate 
side chain introduces a negative charge into the hydrophobic environment of the inhibitor-
binding site. This may lead to interaction with the adjacent accessible K740 side chain and, in 
turn, perturb the alignment of the hinge region. Differences in the hinge region are indeed 
seen in RET structures bound to ATP compared to ZD6474 (Knowles et al. 2006). A possible 
consequence of Y806E would be an altered E805 conformation. The main chain carbonyl of 
E805 makes direct contact with ZD6474, and loss of this interaction may impact on inhibitor 
sensitivity. This may also explain why replacing the E805 side chain by lysine (E805K) 
appears not to affect the actions of ZD6474.  
 
In conclusion, Y806 is involved in RET response to ZD6474. Y806 mutation may be an 
extremely rare primary mutation causing ZD6474 refractoriness. However, mutations at Y806 
and Y806-containing loop including V804, but not at E805, can mediate secondary resistance 
during the treatment of thyroid cancer patients with ZD6474. This information would be 
useful in investigating the mechanisms of lack of response to ZD6474 treatment and 
designing second-line inhibitors to overcome resistance. 
 14 
RET Y806C mutation causes resistance to ZD6474 
DECLARATION OF INTEREST 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
AJ Ryan is a full time employee of Astra Zeneca. M Santoro received an Astra Zeneca 
research grant. 
 
FUNDING 
This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), the 
NOGEC (Naples OncoGEnomic Center), by grants from Italian Ministero della Salute and 
Ministero dell’Università e della Ricerca and by a research grant from Astra Zeneca. T. Guida 
was supported by an AIRC fellowship. S. Anaganti was supported by a Terry Fox Foundation 
fellowship. 
 
ACKNOWLEDGMENTS 
We thank Jean Ann Gilder for text editing and Ciotola Presentation for the art-work.  
 15 
RET Y806C mutation causes resistance to ZD6474 
REFERENCES 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Baselga J 2006 Targeting tyrosine kinases in cancer: the second wave. Science 312 1175-
1178. 
 
Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, 
Brannigan BW, Mohapatra G, Settleman J et al. 2005 Inherited susceptibility to lung cancer 
may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics 37 
1315-1316. 
 
Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 
2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer 
resistance to selective kinase inhibitors. Oncogene 23 6056-6063. 
 
Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A & 
Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases 
by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). Journal of 
Clinical Endocrinology and Metabolism 88 1897-1902. 
 
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, 
Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR 
tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-
7290. 
 
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, 
Bainbridge T, Morich J & Heinrich MC 2005 PDGFRA mutations in gastrointestinal stromal 
 16 
RET Y806C mutation causes resistance to ZD6474 
tumors: frequency, spectrum and in vitro sensitivity to imatinib. Journal of Clinical Oncology 
23 5357-5364.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
 
Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson 
S, Clarke S, Mondellini P, Leyland J, et al 2006 RET is constitutively activated by novel 
tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. 
Cancer Research 66 10179-10187. 
 
Daub H, Specht K & Ullrich A 2004 Strategies to overcome resistance to targeted protein 
kinase inhibitors. Nature Reviews Drug Discovery 3 1001-1010. 
 
Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, 
Murakumo Y, Imai T, Funahashi H et al. 2000 Characterization of intracellular signals via 
tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19 
4469-4475. 
 
Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, Qiao S, Ichihara M 
& Takahashi M 2000 A two-hit model for development of multiple endocrine neoplasia type 
2B by RET mutations. Biochemical and Biophysical Research Communication 268 804-808. 
 
Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, 
Rae P, Mietlowski W, et al 2006 Nilotinib in Imatinib-resistant CML and Philadelphia 
chromosome-positive ALL. New England Journal of Medicine 354 2542-2551. 
 
 17 
RET Y806C mutation causes resistance to ZD6474 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R, Kato M, Suzuki H, 
Takahashi M & Nakashima I 2004 Identification of RET autophosphorylation sites by mass 
spectrometry. Journal of Biological Chemistry 279 14213-14224. 
 
Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF & 
McDonald NQ 2006 Structure and chemical inhibition of the RET tyrosine kinase domain. 
Journal of Biological Chemistry 281 33577-33587. 
 
Krause DS & Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. New 
England Journal of Medicine 353 172-187. 
 
Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature 
Reviews Cancer 5 367-375. 
 
Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K & 
Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET 
proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B 
without codon 918 mutation. Japanese Journal of Cancer Research 90 1-5. 
 
Nardi V, Azam M & Daley GQ 2004 Mechanisms and implications of Imatinib resistance 
mutations in BCR-ABL. Current Opinion in Hematology 11 35-43. 
 
O'Hare T, Corbin AS & Druker BJ 2006 Targeted CML therapy: controlling drug resistance, 
seeking cure. Current Opinion in Genetics and Development 16 92-99. 
 
 18 
RET Y806C mutation causes resistance to ZD6474 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Oriola J, Halperin I, Rivera-Fillat F & Donis-Keller H 2002 The finding of a somatic deletion 
in RET exon 15 clarified the sporadic nature of a medullary thyroid carcinoma suspected to 
be familial. Journal of Endocrinological Investigation 25 25-31. 
 
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG & Varmus H 
2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with 
a second mutation in the EGFR kinase domain. PLoS Medicine 2 e73.  
 
Ryan AJ & Wedge SR 2005 ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase 
activity. British Journal of Cancer 92 S6–S13. 
 
Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, 
Vecchio G, Fusco A & Santoro M 2000 Tyrosines 1015 and 1062 are in vivo 
autophosphorylation sites in ret and ret-derived oncoproteins. Journal of Clinical 
Endocrinology and Metabolism 85 3898-3907. 
 
Santoro M & Carlomagno F 2006 Drug insight: Small-molecule inhibitors of protein kinases 
in the treatment of thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism  2 
42-52.  
 
Santoro M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A & di Fiore PP 
1994 An epidermal growth factor receptor/ret chimera generates mitogenic and transforming 
signals: evidence for a ret-specific signaling pathway. Molecular and Cellular Biology 14 
663-675. 
 
 19 
RET Y806C mutation causes resistance to ZD6474 
Schlumberger M, Carlomagno F, Baudin E, Bidart JM & Santoro M 2008 New therapeutic 
approaches to treat medullary thyroid carcinoma. Nature Clinical Practice Endocrinology and 
Metabolism 4 22-32. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
 
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL & Sawyers CL 2007 
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL 
mutations with altered oncogenic potency. Journal of Clinical Investigation 117 2562-2569. 
 
Sherbenou DW & Druker BJ 2007 Applying the discovery of the Philadelphia chromosome. 
Journal of Clinical Investigation 117 2067-2074. 
 
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, 
Nicaise C, Bleickardt E et al 2006 Dasatinib in Imatinib-resistant Philadelphia chromosome-
positive leukemias. New England Journal of Medicine 354 2531-2541. 
 
Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima 
A, Mitsuyama S, Iwashita T et al 1999 Somatic mutations in RET exons 12 and 15 in 
sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from 
hereditary type. Japanese Journal of Cancer Research 90 1231-1237. 
 
Vidal M, Wells S, Ryan A & Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a 
Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid 
carcinoma. Cancer Research 65 3538-3541. 
 
 20 
RET Y806C mutation causes resistance to ZD6474 
1 
2 
3 
4 
5 
6 
7 
8 
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A & Griffin JD 2007 Second 
generation inhibitors of BCR-ABL for the treatment of Imatinib-resistant chronic myeloid 
leukaemia. Nature Reviews Cancer 7 345-356. 
 
Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch 
W & Schlumberger M 2006 A phase II trial of ZD6474 in patients with hereditary metastatic 
medullary thyroid cancer. Journal of Clinical Oncology 2006 ASCO Annual Meeting 
Proceedings Part I. 24 No. 18S (June 20 Supplement): 5533 
 21 
RET Y806C mutation causes resistance to ZD6474 
LEGENDS TO FIGURES 1 
2  
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Figure 1: Y806 residue determines RET kinase sensitivity to ZD6474 
A) Alignment of ABL and RET kinase domains. P-Loop (phosphate binding-loop) and A-
loop (activation-loop) are indicated. Mutations that cause resistance to imatinib in ABL and 
that correspond to naturally occurring RET mutations are highlighted in grey. For RET, the 
position of the mutated amino acid is reported. B) HEK293 cells were transfected with 
pcDNA 3.1 vectors expressing the indicated RET mutants. Twenty-four hours after 
transfection, cells were serum-starved. Two hours before harvest, cells were treated with 
various ZD6474 doses or vehicle. Cell lysates were immunoblotted with the indicated 
antibodies. Each immunoblot is representative of at least three independent experiments.  
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Figure 2: Effect of alternative RET Y806 substitutions on sensitivity to ZD6474 
A) HEK293 cells were transfected with pcDNA 3.1 vectors expressing the indicated RET 
mutants. Twenty-four hours after transfection, cells were serum-starved and treated (2 h) with 
ZD6474 or vehicle. Cell lysates were analyzed by immunoblot with the indicated antibodies. 
Each immunoblot is representative of at least three independent experiments. B) HEK293 
cells were transfected with RET mutants-expressing vectors. RET proteins were 
immunoprecipitated and subjected to an in vitro kinase assay on a artificial substrate (poly-
Glu-Tyr). Each experiment was performed in triplicate and done at least three times. Results 
from kinase assay have been plotted using a curve-fitting software. SD are indicated. 
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Figure 3: ZD6474 effects on RET mutants intracellular signaling  
A) HEK293 cells were transfected with RET mutants expressing vectors. Twenty-four hours 
after transfection, cells were serum-starved and treated (2 h) with the indicated concentration 
 22 
RET Y806C mutation causes resistance to ZD6474 
of ZD6474. Cell lysates were analyzed by immunoblot with the indicated antibodies. Each 
experiment is representative of at least three assays. B) 1x10
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6 HeLa cells were transiently 
transfected with RET mutants expressing vectors and the AP1-Luc vector pRL-null (a 
plasmid expressing the enzyme Renilla luciferase from Renilla reniformis) served as an 
internal control. Firefly and Renilla luciferase activities are expressed as percentage of 
residual activity compared to cells treated with vehicle. Average results of three independent 
assays ± SD are indicated. The ANOVA Post-Hoc Tukey-Kramer multiple comparison test 
was used to assess statistical significance (P< 0.01). 
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Figure 4. Structure of RET Kinase-ZD6474 complex  
A) The kinase domain of RET in complex with ZD6474. ZD6474 binds in the nucleotide 
binding pocket between the N- and C-lobes. B) Close-up of the nucleotide binding pocket 
showing how the tyrosine 806 (red) interacts with the aliphatic chain of lysine 740 and the 
main chain moiety of alanine 807, and establishes Van der Waals contacts with ZD6474. 
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